



15.04.2020

12:00 - 12:15 Opening and welcome Room B

Moderation: C. Faivre-Finn¹, F. Barlesi², ¹Clinical Oncology Department, The Christie NHS Foundation Trust, Manchester, GB, ²Gustave Roussy - Cancer Campus, Villejuif, FR

12:15 - 12:45 HHH Award lecture Room B

12:15 - 12:45 **HHH Award lecture**

12:45 - 13:15 Welcome reception Hall 1

13:15 - 14:15 Amgen - Targeting KRAS-driven oncogenic signalling in NSCLC Room A

13:15 - 13:35 **An oncologist's perspective**

S. Popat, Royal Marsden Hospital NHS Foundation Trust, London, GB

13:35 - 13:55 **A pathologist's perspective**

R. Büttner, Uniklinik Köln, Köln, DE

13:55 - 14:15 **Panel discussion**

S. Popat¹, R. Büttner², ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Uniklinik Köln, Köln, DE

13:15 - 14:15 Bayer - Precision oncology in practice: A focus on TRK fusion lung cancer Room C

Moderation: J. Mazieres, Thoracic Oncology Department, CHU Toulouse - Hôpital Larrey, Toulouse, FR

13:15 - 13:25 **Welcome and introduction**

J. Mazieres, CHU Toulouse - Hôpital Larrey, Toulouse, FR

13:25 - 14:10 **Cases from the clinic: Practical identification and treatment**

J. Mazieres¹, A. Drilon², ¹CHU Toulouse - Hôpital Larrey, Toulouse, FR, ²Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

14:10 - 14:15 **Meeting close**

J. Mazieres, CHU Toulouse - Hôpital Larrey, Toulouse, FR



14:30 - 16:00 Multimodality treatment in early stage Room B

Moderation: J. Hellyer¹, E. Fadel², ¹Department Of Oncology, Stanford Comprehensive Cancer Institute, Stanford, US, ²Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, FR

14:30 - 14:40 **Presentation of case**

J. Hellyer, Stanford Comprehensive Cancer Institute, Stanford, US

14:40 - 14:55 **Controversies in the surgical treatment of early stage NSCLC**

E. Fadel, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, FR

14:55 - 15:10 **Controversies in SBRT in early stage NSCLC**

K. Franks, St. James's University Hospital Leeds, Leeds, GB

15:10 - 15:25 **Is there a role for I-O in the peri-operative setting for NSCLC?**

H. Wakelee, Stanford University, Stanford, US

15:25 - 15:40 **Management decision**

15:40 - 16:00 **Discussion**



14:30 - 16:00 The e-cigarette: The devil in disguise? Room A
Moderation: A.-M. Dingemans¹, W. De Kanter², ¹Pulmonology Department, Erasmus MC - University Medical Center, Rotterdam, NL, ²Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

14:30 - 14:50 **E-cigarettes and effectiveness in smoking cessation**

J. Jassem, Medical University of Gdansk, Gdansk, PL

14:50 - 15:10 **Vaping at middle and high schools**

W. De Kanter, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

15:10 - 15:30 **E-cigarettes: Safe vaping tool?**

15:30 - 15:50 **E-cigarettes: Epidemiology and (EU) politics**

F. Filippidis, Imperial College London-South Kensington Campus, London, GB

15:50 - 16:00 **Q&A**

14:30 - 16:00 Management of I-O adverse events Room C
Moderation: M. Garassino¹, M.R. Garcia Campelo², ¹Thoracic Unit, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²Dept. Medical Oncology, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES

14:30 - 14:50 **Incidence and outcome of I-O adverse events from clinical trials**

M.R. Garcia Campelo, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES

14:50 - 15:10 **I-O related adverse events in higher-risk patients**

J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

15:10 - 15:30 **How to manage I-O related adverse events**

O. Lambotte, CHU de Bicêtre, Le Kremlin Bicetre, FR

15:30 - 15:50 **Predictive biomarkers for I-O related adverse events**

M. Sebastian, Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE

15:50 - 16:00 **Q&A**



16:00 - 16:30	Coffee break	Hall 1
16:00 - 16:30	YO Mentorship session	Hall 1 - Catch up corner
	Moderation: B. Besse ¹ , S. Novello ² , F. Mcdonald ³ , M. O'Brien ³ , ¹ Dept Of Cancer Medicine, Institut Gustave Roussy, Villejuif, FR, ² Oncology Dept., Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ³ Royal Marsden Hospital NHS Foundation Trust, London, GB	
16:30 - 18:00	Brain metastases are not all the same	Room B
	Moderation: U. Ricardi ¹ , J. Jassem ² , ¹ University Of Turin, Department Of Oncology, Azienda Ospedaliero Universitaria San Giovanni Battista di Torino, Torino, IT, ² Medical University of Gdansk, Gdansk, PL	
16:30 - 16:50	Surgical indications and timing	
	<u>M. De Praeter</u> , University Hospital Antwerp (UZA), Antwerp, BE	
16:50 - 17:10	State of the art and future perspective from radiation oncology	
	<u>U. Ricardi</u> , Azienda Ospedaliero Universitaria San Giovanni Battista di Torino, Torino, IT	
17:10 - 17:30	Targeted therapy for oncogene addicted NSCLC	
	<u>J.C.-H. Yang</u> , National Taiwan University Hospital, Taipei city, TW	
17:30 - 17:50	Systemic treatment for non-oncogene addicted NSCLC	
	<u>L. Hendriks</u> , Maastricht University Medical Center (MUMC), Maastricht, NL	
17:50 - 18:00	Q&A	



- 16:30 - 18:00** **What's next in the management of SCLC?** **Room C**
Moderation: C. Faivre-Finn¹, S. Liu², ¹Clinical Oncology Department, The Christie NHS Foundation Trust, Manchester, GB, ²Medical Oncology, Lombardi Cancer Center Georgetown University, Washington, US
- 16:30 - 16:50 **What will preclinical models for SCLC provide us for the future?**
A. Berns, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL
- 16:50 - 17:10 **Controversies in radiotherapy**
C. Faivre-Finn, The Christie NHS Foundation Trust, Manchester, GB
- 17:10 - 17:30 **I-O in SCLC**
S. Liu, Lombardi Cancer Center Georgetown University, Washington, US
- 17:30 - 17:50 **Novel agents in SCLC: Updates**
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES
- 17:50 - 18:00 **Q&A**



- 16:30 - 18:00 Proffered Paper 1** **Room A**
Moderation: A.-M. Dingemans¹, M. Pérol², ¹Pulmonology Department, Erasmus MC - University Medical Center, Rotterdam, NL, ²Medical Oncology Dept, Centre Léon Bérard, Lyon, FR
- 16:30 - 16:45 **430 - Trends of Incidence and Burden of Metastatic Disease at the Time of Diagnoses of Lung Cancer after Implementation of Low Dose CT Screening in United States**
P. Bedi¹, M. Rai¹, S. Siddappa Malleshappa¹, P. Neupane², C. Huang², J. Zhang², K. Mehta³, ¹University of Pittsburgh Medical Center, Pittsburgh, US, ²University of Kansas Medical Center, Kansas City, US, ³UPMC Hillman Cancer Center, Pittsburgh, US
- 16:45 - 17:00 **Invited Discussant 430**
M. Pérol, Centre Léon Bérard, Lyon, FR
- 17:00 - 17:15 **One LBA TBC**
- 17:15 - 17:30 **2240 - First-Line Tyrosine Kinase Inhibitor With or Without Aggressive Upfront Local Radiation Therapy In Patients With EGFRm Oligometastatic Non-Small-Cell Lung Cancer: Interim Results of A RandomizedPhase III, Open-Label ClinicalTrial (SINDAS) (NCT02893332).**
M.W. Wu¹, M.X. Zhou¹, X. Luo¹, Y.F. Bai¹, X.S. Wang¹, M. Zeng², ¹Hospital of University of Electronic Science and Technology of China and Sichuan Provincial People's Hospital, Chengdu, CN, ²Sichuan Provincial People's Hospital. Sichuan Medical Science Academy, Chengdu, CN
- 17:30 - 17:45 **Invited Discussant One LBA TBC and 2240**
R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL



- 18:15 - 19:15 Novartis Oncology - Raising the bar for better outcomes in NSCLC Room A**
Moderation: A. Greystoke, Medical Oncology Department, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB
- 18:15 - 18:25 **Welcome and introduction: Preparing for the future of NSCLC treatment**
A. Greystoke, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB
- 18:25 - 18:50 **Tumor-promoting inflammation: The emerging role of IL-1 in NSCLC**
M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE
- 18:50 - 19:10 **Novel oncogenic drivers: Addressing the remaining unMET needs**
E. Smit, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL
- 19:10 - 19:15 **Meeting closure**
A. Greystoke, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB



16.04.2020

08:00 - 09:00 What you need to know about assessing response after radiotherapy Room B

Moderation: Y. Lievens¹, J.-Y. Gaubert², M. Scheffler³, ¹Radiation Oncology Dept., UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ²Assistance Publique Hopitaux de Marseille, Marseille, FR, ³Department I Of Internal Medicine, Uniklinik Köln, Cologne, DE

08:00 - 08:15 **Case presentation**

M. Scheffler, Uniklinik Köln, Cologne, DE

08:15 - 08:30 **Perspective 1 (Radiation oncology)**

Y. Lievens, UZ Gent - Universitair Ziekenhuis Gent, Gent, BE

08:30 - 08:45 **Perspective 2 (Radiology)**

J.-Y. Gaubert, Assistance Publique Hopitaux de Marseille, Marseille, FR

08:45 - 09:00 **Discussion**

08:00 - 09:00 How to read the pathological analyses of surgical specimen Room C

Moderation: S. Lantuejoul¹, A. Brunelli², L. Righi³, ¹Centre Léon Bérard, Lyon, FR, ²St. James's University Hospital Leeds, Leeds, GB, ³University of Turin, Torino, IT

08:00 - 08:15 **Case presentation**

L. Righi, University of Turin, Torino, IT

08:15 - 08:30 **Perspective 1 (Surgery)**

A. Brunelli, St. James's University Hospital Leeds, Leeds, GB

08:30 - 08:45 **Perspective 2 (Pathology)**

S. Lantuejoul, Centre Léon Bérard, Lyon, FR

08:45 - 09:00 **Discussion**

08:00 - 09:00 Mini oral 1 Room A

Moderation: D. Planchard¹, M. Garassino², S. Pilotto³, L. Mezquita¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Thoracic Unit, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ³Medical Oncology, AOU Integrata Borgo Roma Verona, Verona, IT

08:00 - 08:05 **One LBA TBC**



08:05 - 08:10 **One LBA TBC**

08:10 - 08:15 **1280 - 4-Year survival in randomised Phase II (POPLAR) and Phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC**

J. Mazieres¹, A. Rittmeyer², S. Gadgeel³, T. Hida⁴, D. Gandara⁵, D. Cortinovis⁶, F. Barlesi⁷, W. Yu⁸, C. Matheny⁹, M. Ballinger¹⁰, K. Park¹¹, ¹CHU Toulouse - Hôpital Larrey, Toulouse, FR, ²LKI Lungenfachklinik Immenhausen, Immenhausen, DE, ³Karmanos Cancer Institute, Detroit, US, ⁴Aichi Cancer Center Hospital, Nagoya, JP, ⁵University of California Davis Cancer Center, Sacramento, US, ⁶Azienda Ospedaliera S. Gerardo, Monza, IT, ⁷Gustave Roussy - Cancer Campus, Villejuif, FR, ⁸Genentech, Inc., South San Francisco, US, ⁹Genentech, Inc. - Member of the Roche Group, South San Francisco, US, ¹⁰Genentech, South San Francisco, US, ¹¹Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

08:15 - 08:20 **1290 - Development and validation of a deep learning algorithm for scoring PD-L1 expression in advanced metastatic Non-Small Cell Lung Cancer**

L. Hondelink¹, J. Von Der Thüsen¹, S. Blom², D. Cohen¹, ¹Leiden University Medical Center (LUMC), Leiden, NL, ²AiForia Technologies Oy, Helsinki, FI

08:20 - 08:25 **1300 - Characterization of responders to nivolumab (NIVO) + ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC) in CheckMate 227 Part 1**

J. Brahmer¹, T.-E. Ciuleanu², M. Schenker³, C. Audigier-Valette⁴, B. Zurawski⁵, H. Linardou⁶, S.-W. Kim⁷, G. Otterson⁸, P. Salman⁹, E. De La Mora Jimenez¹⁰, K. Lesniewski-Kmak¹¹, S. Ahmed¹², I. Albert¹³, F. Barlesi¹⁴, K. Feeney¹⁵, N. Frickhofen¹⁶, A. Li¹⁷, S. Rabindran¹⁷, M. Hellmann¹⁸, ¹Johns Hopkins Hospital, Baltimore, US, ²Prof. Dr. Ion Chiricuta Institute of Oncology Day Care Dep, Cluj-Napoca, RO, ³SF. Nectarie Oncology Center, Craiova, RO, ⁴Hôpital Sainte-Musse, Toulon, FR, ⁵Ambulatorium Chemioterapii, Bydgoszcz, PL, ⁶Metropolitan Hospital, Neo Faliro, GR, ⁷Asan Medical Center, Seoul, KR, ⁸The Ohio State University, Columbus, US, ⁹Fundacion Arturo Lopez Perez, Santiago, CL, ¹⁰Instituto Jalisciense De Cancerología, Guadalajara, MX, ¹¹Oddzial Onkologii I Radioterapii Szpital Morski Im. Pck, Gdynia, PL, ¹²Leicester Royal Infirmary, Leicester, GB, ¹³Matrai Gyogyintezet, Matrahaza, HU, ¹⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁵Notre Dame University Fremantle and Edith Cowan University Joondalup, Perth, AU, ¹⁶Helios Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, DE, ¹⁷Bristol-Myers Squibb, Princeton, US, ¹⁸Memorial Sloan-Kettering Cancer Center, New York, US

08:25 - 08:30 **1310 - KEYNOTE-021 cohort G long-term follow-up: first-line (1L) pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC**

M. Awad¹, S.M. Gadgeel², H. Borghaei³, A. Patnaik⁴, J.C.-H. Yang⁵, S.F. Powell⁶, R.D. Gentzler⁷, R.G. Martins⁸, J.P. Stevenson⁹, M. Altan¹⁰, S.I. Jalal¹¹, A. Panwalkar¹², M. Gubens¹³, L.V. Sequist¹⁴, S. Saraf¹⁵, B. Zhao¹⁵, B. Piperdi¹⁵, C.J. Langer¹⁶, ¹Dana Farber Cancer Institute, Boston, US, ²Thoracic Oncology, Detroit, US, ³Hematology and Oncology, Philadelphia, US, ⁴Clinical Research, San Antonio, US, ⁵Department of Oncology, Taipei, TW, ⁶Oncology, Sioux Falls, US, ⁷Hematology/Oncology, Charlottesville, US, ⁸Medicine, Seattle, US, ⁹Taussig Cancer Institute, Cleveland, US, ¹⁰Thoracic/Head



and Neck Oncology, Houston, US, ¹¹Internal Medicine, Indianapolis, US,
¹²Hematology/Oncology, Fargo, US, ¹³Medical Oncology, San Francisco, US,
¹⁴Hematology/Oncology, Boston, US, ¹⁵Merck & Co., Inc., Kenilworth, US, ¹⁶Department
of Medicine, Abramson Cancer Center, Philadelphia, US

- 08:30 - 08:35 **2380 - Use of potentially inappropriate medication in elderly patients with lung cancer in the last month of life**
L. Ham¹, E. Geijteman², M. Aarts¹, J. Kuiper³, P. Kunst¹, N. Raijmakers¹, L. Visser⁴, L. Van Zuylen², E. Brokaar⁴, H. Fransen¹, ¹IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL, ²Erasmus MC Cancer Institute, Rotterdam, NL, ³PHARMO Institute for Drug Outcomes Research, Utrecht, NL, ⁴Haga Teaching Hospital, The Hague, NL
- 08:35 - 08:40 **2390 - Prognosis of pulmonary resection for non-small cell lung cancer patients with interstitial lung abnormalities**
H. Tang¹, Y. Ren¹, C. Chen², ¹Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, CN, ²Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN
- 08:40 - 09:00 **Discussion led by Moderators**
L. Mezquita Pérez¹, S. Pilotto², ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²AOU Integrata Borgo Roma Verona, Verona, IT



09:15 - 10:45 YO case discussion: Challenges in clinical oncology **Room A**
Moderation: K.H.J. Lim, Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, GB

09:15 - 09:22 **Case 1: Sequence of treatment of oncogene driven NSCLC patients**

09:22 - 09:37 **Mentor guided discussion**

J. Corral Jaime, Hospital Universitario Virgen del Rocío, Seville, ES

09:37 - 09:44 **Case 2: Immunotherapy for SCLC**

09:44 - 09:59 **Mentor guided discussion**

R. Califano, The Christie NHS Foundation Trust, Manchester, GB

09:59 - 10:06 **Case 3: Treatment of metastatic NSCLC with absent PD-L1 expression and without oncogene addiction**

10:06 - 10:21 **Mentor guided discussion**

G. Mountzios, University of Athens School of Medicine Clinical Therapeutics, Athens, GR

10:21 - 10:28 **Case 4: Treatment of patients with NSCLC and brain metastases**

10:28 - 10:43 **Mentor guided discussion**

L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL



09:15 - 10:45 Management of elderly **Room C**
Moderation: J. Van Loon, Maastricht University Medical Centre (MUMC)-MAASTRO clinic, Maastricht, NL

09:15 - 09:25 **Presentation of case**

09:25 - 09:40 **Are elderly different?**

L. Crinò, Istituto Tumori della Romagna I.R.S.T., Meldola, IT

09:40 - 09:55 **Implementing geriatric assessment into the MDT assessment of the older patients**

A. O'Donovan, Trinity College Dublin, Dublin, IE

09:55 - 10:10 **Assessing biological age in lung cancer: A useful tool?**

A. Greystoke, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB

10:10 - 10:25 **Management decision**

10:25 - 10:45 **Discussion**



09:15 - 10:45	ESMO Colloquium supported by Lilly - EGFR TKI: Single agent or in combination?	Room B
	Moderation: E. Garon ¹ , D. Planchard ² , ¹ Medicine; Division Of Heme/onc, UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ² Institut Gustave Roussy, Villejuif, FR	
09:15 - 09:30	EGFR TKI in first-line: First/second generation TKI or osimertinib upfront?	
	<u>D. Planchard</u> , Institut Gustave Roussy, Villejuif, FR	
09:30 - 09:45	Should EGFR TKI be used in combination with chemotherapy?	
	<u>E. Felip</u> , Vall d'Hebron University Hospital, Barcelona, ES	
09:45 - 10:00	What is the contribution of anti-angiogenic added to EGFR TKI?	
	<u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	
10:00 - 10:15	Do immune check-point inhibitors work in EGFR mutant?	
	<u>E. Garon</u> , UCLA Hematology/Oncology Santa Monica, Santa Monica, US	
10:15 - 10:30	One case of EGFR mutant	
	<u>C.E. Onesti</u> , Centre Hospitalier Universitaire Sart Tilman, Liège, BE	
10:30 - 10:45	Expert panel discussion: Questions from the audience	
10:45 - 11:15	Coffee break	Hall 1
10:45 - 11:15	YO Mentorship session	Hall 1 - Catch up corner
	Moderation: M. Garassino ¹ , A.-M. Dingemans ² , R.A. Stahel ³ , J. Haanen ⁴ , ¹ Thoracic Unit, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ² Pulmonology Department, Erasmus MC - University Medical Center, Rotterdam, NL, ³ University Hospital Zürich, Zurich, CH, ⁴ Medical Oncology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL	



11:15 - 12:45 The eternal debate in stage III Room B
Moderation: I. Browne, Department Of Medical Oncology, Mid-western Cancer Centre, University Hospital Limerick, Limerick, IE

11:15 - 11:25 **Presentation of case**

I. Browne, University Hospital Limerick, Limerick, IE

11:25 - 11:40 **What is the best local treatment? Surgery**

G. Massard, C.H.U. Strasbourg-Nouvel Hopital Civil, Strasbourg, FR

11:40 - 11:55 **What is the best local treatment? Radiation therapy**

M. Werner-Wasik, Kimmel Cancer Center-Thomas Jefferson University, Philadelphia, US

11:55 - 12:10 **Don't forget the systemic treatment**

L. Coate, University Hospital Limerick, Dooradoyle, IE

12:10 - 12:25 **Management decision**

12:25 - 12:45 **Discussion**

11:15 - 12:45 Mesothelioma: Will I-O shape the future? Room C
Moderation: J. Edwards¹, R.A. Stahel², ¹Northern General Hospital-Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, ²University Hospital Zürich, Zurich, CH

11:15 - 11:35 **Molecular risk factors and predictive biomarkers**

G. Scagliotti, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT

11:35 - 11:55 **What is the standard of care in front-line and beyond?**

D. Fennell, University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, Leicester, GB

11:55 - 12:15 **Indication for lung-sparing radiotherapy**

A. Rimner, Memorial Sloan Kettering Cancer Center, New York, US

12:15 - 12:35 **The role of immunotherapy**

L. Greillier, Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR

12:35 - 12:45 **Q&A**



11:15 - 12:45 Lung cancer screening: The end of the beginning Room A

Moderation: J. Mazieres¹, P. Van Schil², ¹Thoracic Oncology Department, CHU Toulouse - Hôpital Larrey, Toulouse, FR, ²Department Of Thoracic And Vascular Surgery, University Hospital Antwerp (UZA), Edegem, BE

11:15 - 11:35 Nelson and NSLT: Are the results similar?

J. Field, Royal Liverpool University Hospital, Liverpool, GB

11:35 - 11:55 Implementation of screening programmes

S. Couraud, Centre Hospitalier Lyon Sud, Pierre Bénite, FR

11:55 - 12:15 Novel screening approaches

P. Crosbie, The University of Manchester, Manchester, GB

12:15 - 12:35 Optimal management of lesions discovered at screening

G. Veronesi, Università Vita e Salute San Raffaele Milano, Milan, IT

12:35 - 12:45 Q&A

12:45 - 13:30 Poster Display and lunch break Hall 1

12:45 - 12:45 Tumour biology and pathology

12:45 - 12:45 2P - An integrated Imaging Hyperspectral Cell Sociology platform to assess TME changes in lung cancer and its potential to predict lung cancer outcomes.

M. Guillaud¹, P. Gallagher², K. Enfield², S. Martin², E. Marshall², J. English², S. Lam², W. Lam², C. Macaulay², ¹BC Cancer Research Center, Vancouver, CA, ²BC Cancer, Vancouver, CA

12:45 - 12:45 3P - Primary lung NUT-carcinoma; an underdiagnosed entity with limited treatment options.

Z. Gatalica, J. Xiu, J. Swensen, Caris Life Sciences - Arizona Office, Phoenix, US

12:45 - 12:45 4P - Schwann cells promote lung cancer progression by promoting the M2 polarization of macrophage

Y. Zhou¹, J. Li², H. Zhong³, ¹Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, ²Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ³Shanghai Jiao Tong University Affiliated Chest Hospital, Shanghai, CN

12:45 - 12:45 5P - Inhibition of Fatty Acid Synthase (FASN) activity induces cytotoxicity on Gefitinib- and Osimertinib-resistant EGFR-mutated non-small cell lung cancer cells

E. Polonio-Alcalá¹, S. Palomeras², J. Bosch-Barrera³, R. Porta-Balanya⁴, J. Relat⁵, J.



Ciurana², S. Ruiz-Martínez², T. Puig³, ¹Universitat de Girona-Facultat de Medicina, Girona, ES, ²University of Girona, Girona, ES, ³ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta Hospital Universitari Josep Trueta), Girona, ES, ⁴ICO Girona - Institut Català d'Oncologia Girona, Girona, ES, ⁵University of Barcelona, Santa Coloma de Gramenet, ES

- 12:45 - 12:45 **7P - Prevalence and type of uncommon NSCLC EGFR mutations in the Bulgarian population**
S. Bichev¹, N. Chilingirova², T. Dineva³, S. Popovska³, ¹National Genetics Laboratory, Sofia, BG, ²National Center of Oncology-SBALO EAD, Sofia, BG, ³Medical University Pleven, Pleven, BG
- 12:45 - 12:45 **9P - Expression of programmed death ligand-1 (PD-L1) on cytological smears in advanced non small cell lung cancer: a prospective cohort study**
C. Ricci, F. Dall'Olio, E. Capizzi, F. Giunchi, S. Zagnoni, C. Ceccarelli, L. Casolari, F. Gelsomino, R. Trisolini, M. Fiorentino, A. Ardizzoni, AOU Policlinico S. Orsola-Malpighi, Bologna, IT
- 12:45 - 12:45 **10P - DAB2IP inhibits metastasis in NSCLC by governing cell-matrix and cell-cell adhesions**
S. Yang¹, J. Min², ¹The First Affiliated Hospital of Chongqing Medical University, Chongqing, CN, ²Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US
- 12:45 - 12:45 **11P - miR-300 desensitizes human lung cancer cells to radiation by targeting apaf1**
J. Wang, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, CN
- 12:45 - 12:45 **12P - The neuroprotective effect of afatinib on hemin-induced neurotoxicity in primary cultured cortical neurons**
M.-Y. Lin¹, H. Huang², J.C.-H. Yang³, ¹National Yang-Ming University, Taipei City, TW, ²Department of Medical Research, Taipei Veterans General Hospital, Taipei, TW, ³National Taiwan University Hospital, Taipei city, TW
- 12:45 - 12:45 **Translational research**
- 12:45 - 12:45 **14P - STING pathway expression identifies non-small cell lung cancers with an immune-responsive phenotype and is activated by chemotherapy**
C.M. Della Corte¹, T. Sen², C. Gay³, K. Ramkumar³, L. Diao³, R. Cardnell³, L. Rodriguez³, A. Stewart³, V. Papadimitrakopoulou⁴, Q. Wang³, D. Peng³, M. Negrao³, J. Fujimoto³, F. Skoulidis³, J. Heymach³, J. Wang³, D. Gibbons³, L. Byers³, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²MSK, new york, US, ³MD Anderson, HOUSTON, US, ⁴MD Anderson Cancer Center, Houston, US
- 12:45 - 12:45 **15P - The Early Landscape of Immune Cell Subsets in Metastatic NSCLC Patients treated with immune checkpoint inhibitors**



J.-G. Zhou¹, U. Gaip², M. Hecht², A. Donaubaue², B. Frey², I. Becker², S. Rutzner², R. Sun³, H. Ma⁴, R. Fietkau², E. Deutsch⁵, ¹Zunyi Medical College Affiliated Hospital, Zunyi, CN, ²Universitätsklinikum Erlangen, Erlangen, DE, ³Institut Gustave Roussy, Villejuif, FR, ⁴Zunyi Medical College Affiliated Hospital, Zunyi City, CN, ⁵Gustave Roussy Cancer Campus, Villejuif, FR

- 12:45 - 12:45 **16P - The microbiome at work: Desulfovibrio and Bifidobacterium associated with decreased immunotherapy-related toxicities in lung cancer.**
J. Zhang¹, J. Chau², M. Yadav³, M. Furqan³, K. Mercer³, E. Eastman³, S. Shahi³, Q. Dai³, C. Chan³, G. Weiner³, T. Hejleh³, A. Mangalam³, ¹University of Kansas Medical Center, Kansas City, US, ²University of Iowa - Hospital, Iowa City, US, ³University of Iowa Hospitals and Clinics, Iowa City, US
- 12:45 - 12:45 **17P - PD-1T TILs as biomarker for clinical benefit of anti-PD-1 therapy in Non-Small Cell Lung Cancer**
K. Hummelink, V. Van Der Noort, M. Muller, R.D. Schouten, D. Peters, W.S.M.E. Theelen, M.M. Van Den Heuvel, A. Broeks, G.A. Meijer, E.F. Smit, J.B.A.G. Haanen, T.N. Schumacher, K. Monkhorst*, D.S. Thommen*, Netherlands Cancer Institute, Amsterdam, NL
- 12:45 - 12:45 **18P - Radiomics Network Model of Predicting Tumor Microenvironment of Non-Small Cell Lung Cancer**
W. Yu¹, X.-L. Fu², H.-L. Gu², Y. Li², ¹Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, ²Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN
- 12:45 - 12:45 **19P - PD-L1 assessment on Circulating Tumor Cells (CTCs) as prognostic biomarker in Advanced Non Small Cell Lung Cancer (A-NSCLC) patients treated with Immune Checkpoint Inhibitors (ICI)**
F. Dall'Olio¹, L. Casolari¹, A. De Giglio², B. Melotti¹, F. Sperandi¹, F. Formica¹, G. Nuvola¹, C. Parisi¹, F. Gelsomino¹, K. Rihawi³, G. Grilli¹, F. Fontana⁴, M. Fiorentino¹, A. Ardizzoni², ¹AOU Policlinico S. Orsola-Malpighi, Bologna, IT, ²Policlinico S. Orsola-Malpighi, Bologna, IT, ³Azienda ospedaliero-universitaria S. Maria della Misericordia, Udine, IT, ⁴Silicon Biosystem, Bologna, IT
- 12:45 - 12:45 **20P - PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: A large study of 1,370 cases in China**
C.C. Li¹, B. Cheng¹, J. Li¹, S. Xiong¹, J. He², W. Liang¹, ¹The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ²The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China, Guangzhou, CN
- 12:45 - 12:45 **21P - PD-L1 expression and T cells infiltration in patients with non-small cell lung cancer and tuberculosis**
X. Xu, Y. Fan, Zhejiang Cancer Hospital, Hangzhou, CN
- 12:45 - 12:45 **22P - Adenosine pathway and exhaustion markers in peripheral T cell correlate with benefit from immunotherapy in advanced non-small cell lung cancer**



L. Moliner¹, M.A. Galindo-Campos², M. Hardy-Werbin³, R. Del Rey-Vergara², O. Arpi², X. Villanueva¹, S. Gonzalez², Á. Taus¹, P. Rocha⁴, E. Arriola Aperribay¹, ¹Hospital del Mar, Barcelona, ES, ²IMIM (Hospital del Mar Medical Research Institute), Barcelona, ES, ³ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ⁴MD Anderson Cancer Center, Houston, US

- 12:45 - 12:45 **23P - MDM2 Amplification and Hyperprogression Following Treatment with Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer**
D. Cowzer, S. Blazkova, P. Donnellan, S. Henry, S. Hynes, University College Hospital Galway, Galway, IE
- 12:45 - 12:45 **24P - The Clinical Utility of Circulating Free DNA (cfDNA) analysis in Non Small Cell Lung Cancer (NSCLC) in the United Kingdom**
M. Carter¹, W. Griffiths², G. Laviste¹, A. Bridgwood², S. Rafee¹, A. Ortega Franco³, S. Hall², F. Blackhall¹, A. Greystoke², ¹The Christie NHS Foundation Trust, Manchester, GB, ²The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ³The Clatterbridge Cancer Centre, Liverpool, GB
- 12:45 - 12:45 **25P - Identification of Somatic Copy Number Variations in Plasma Cell Free DNA correlating with Intrinsic Resistances to EGFR Targeted Therapy in T790M Negative Non-Small Cell Lung Cancer**
S. Zhang¹, L. Zhu², J. Liang¹, B. Xia², Y. Xu¹, Z. Qian³, S. Ma¹, ¹Hangzhou First People's Hospital, Hangzhou, CN, ²Hangzhou cancer hospital, Hangzhou, CN, ³Prophet Genomics Inc, San Jose, US
- 12:45 - 12:45 **26P - The prognostic impact of Homeobox A9 methylation status from circulating DNA in advanced non-small cell lung cancer**
S. Wen¹, T. Hansen², R. Andersen¹, C. Nyhus¹, H. Hager¹, O. Hilberg¹, A. Jakobsen¹, ¹Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK, ²Vejle Hospital, Vejle, DK
- 12:45 - 12:45 **27P - Ultrasensitive Detection of EGFR Mutations on plasma EV-RNA in NSCLC**
L. Pasini¹, M. Notarangelo², M. Burgio¹, L. Crinò³, E. Chiadini³, P. Ulivi⁴, V.G. D'Agostino², ¹IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS S.r.l., Meldola, IT, ²University of Trento, Trento, IT, ³Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ⁴Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT
- 12:45 - 12:45 **28P - Predicting KRAS mutation of NSCLC based on laboratory blood test profiling**
L. Ou¹, W. Liang², L. Liu¹, W. Zeng¹, L. Huang¹, Q. Deng¹, H. Tang¹, Z. Chen¹, Y. Lin¹, ¹The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ²The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN
- 12:45 - 12:45 **29P - Tracing genes involved in anxiety and cancer in peripheral blood**
R. Rosell¹, M. Fernández-Bruno², C. Pedraz³, J.W.P. Bracht⁴, M. Filipka³, A. Aguilar⁵, J.J. García⁶, C. Cabrera⁶, M. González-Cao⁶, S. Viteri-Ramírez⁶, I. Chaib³, ¹HUGTP - Hospital Universitario Germans Trias i Pujol, Badalona, ES, ²Centro Integral Oncológico Clara



Campal, Santiago de Compostela, A Coruna, ES, ³Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, ES, ⁴Pangaea Oncology, IOR, Quirón-Dexeus University Institute, Barcelona, ES, ⁵Instituto Oncológico Dr Rosell (IOR), Hospital Universitario Quirón-Dexeus, Barcelona, ES, ⁶Instituto Oncológico Dr. Rosell (IOR- Quirón-Dexeus University Institute), Barcelona, ES

- 12:45 - 12:45 **30P - Development of personalised treatment recommendations using fly avatars**
N. Villegas¹, C. De Miguel Vijandi², A. Sawala², A. Chai¹, ¹My Personal Therapeutics, London, GB, ²My Personal Therapeutics, W EZ, GB
- 12:45 - 12:45 **31P - Association of chromosome 3p21.1 deletion in pulmonary lymphoepithelioma-like carcinoma with poor overall survival**
S.L. Chau¹, J.H.M. Tong², R.W.M. Lung², J.S.H. Kwan², C. Chow², K.W. Lo², K.F. To², ¹Prince of Wales Hospital, Sha Tin, HK, ²The Chinese University of Hong Kong, Hong Kong, HK
- 12:45 - 12:45 **32P - Prognostic value of tumor epithelial-mesenchymal transition in non-small cell lung cancer patients after radical surgery**
A. Basharina¹, T. Bogush¹, S. Kaliuzhny¹, E. Bogush¹, V. Kirsanov², N. Vichlzantseva¹, V. Kosorukov¹, ¹N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ²FSAEI HE I.M. Sechenov First MSMU MOH Russia (Sechenovskiy University), Moscow, RU
- 12:45 - 12:45 **33P - DSG3 and DSC3 are novel prognostic factors in patients with non-small cell lung cancer**
C. Xu¹, X. Li², W. Wang³, L. Lei³, W. Pan⁴, Y. Zhu², M. Fang³, T. Lv⁵, Y. Song⁵, ¹Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, ²Zhejiang Rongjun Hospital, Jiaxing, CN, ³Zhejiang Cancer Hospital, Hangzhou, CN, ⁴College of Medicine, Jiaxing University, Jiaxing, CN, ⁵Jinling Hospital, Nanjing, CN
- 12:45 - 12:45 **34P - Chalcomoracin inhibits cell proliferation and increases sensitivity to radiation treatment in non-small cell lung cancer cells through endoplasmic reticulum stressed mediated paraptosis.**
S. Zhang¹, X. Zhang¹, J. Liang², H. Fang³, H. Huang¹, Y. Zhao¹, X. Chen¹, S. Ma¹, ¹Hangzhou First People's Hospital, Hangzhou, CN, ²Hangzhou First People's Hospital, Hangzhou, CN, ³Xiaoshan Hospital, Hangzhou, CN
- 12:45 - 12:45 **35P - Clinical And Real-World Outcomes In Patients With Exon 20 Insertion Mutation Epidermal Growth Factor Receptor-Positive (EGFR+) Non-Small Cell Lung Cancer (NSCLC) - A Meta-Analysis**
A. Forsythe¹, H. Lin², D. Tomaras³, V. Crossland², ¹Purple Squirrel Economics, New York, US, ²Millennium Pharmaceutical (subsidiary of Takeda Pharmaceutical Company Ltd), Cambridge, US, ³Purple Squirrel Economics, Montreal, CA
- 12:45 - 12:45 **36P - Exosome-Transmitted IncARSR Promotes Crizotinib Resistance in Lung Carcinoma by regulating PI3K/Akt/mTOR signaling pathway**
X. Li¹, C. Xu², W. Wang³, L. Lei³, W. Pan⁴, Y. Zhu¹, M. Fang³, T. Lv⁵, Y. Song⁵, ¹Zhejiang



Rongjun Hospital, Jiaxing, CN, ²Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, ³Zhejiang Cancer Hospital, Hangzhou, CN, ⁴College of Medicine, Jiaxing University, Jiaxing, CN, ⁵Jinling Hospital, Nanjing, CN

- 12:45 - 12:45 **37P - Investigating and Exploiting Metabolic Vulnerabilities in STK11-mutant Lung Cancer**
Y. Gao, H. Yang, Inselspital - University Hospital Bern - Universitätsklinik für Thoraxchirurgie, Bern, CH
- 12:45 - 12:45 **38P - A Kinome CRISPR screen in FGFR-amplified lung cancer**
Z. Yang¹, S. Liang¹, R. Schmid¹, R.-W. Peng², ¹University of Bern - DBMR, Bern, CH, ²Inselspital - University Hospital Bern - Universitätsklinik für Thoraxchirurgie, Bern, CH
- 12:45 - 12:45 **39P - Co-Treatment with Anlotinib Augments Response to Trametinib in Kras-mutant NSCLC**
M. Hu¹, Y. Zhao², B. Zhang², Y. Zhang¹, S. Wang², B. Han², ¹Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, ²Shanghai Chest Hospital, Shanghai, CN
- 12:45 - 12:45 **40P - Prognostic and clinical significance of CD40 expression in non-small-cell lung cancer (NSCLC) patients**
F.-I. Dimitrakopoulos¹, A. Kottorou¹, A. Antonacopoulou², A. Nikolakopoulos¹, N. Panagopoulos³, D. Dougenis³, M. Melachrinou⁴, A. Koutras¹, T. Makatsoris¹, V. Tzelepi⁵, H. Kalofonos⁶, ¹University Hospital Patras, Patras, GR, ²University of Patras, Patras, GR, ³Department of Cardiothoracic Surgery, Medical School, University of Patras, Greece, Patras, GR, ⁴Department of Pathology, Medical School, University of Patras, Greece, Patras, GR, ⁵424 General Military Hospital, Serres, GR, ⁶Molecular Oncology Laboratory, Medical School, University of Patras, Greece, Patras, GR
- 12:45 - 12:45 **41P - Natural Killer Antibody-Dependent Cell Cytotoxicity (NK-ADCC) predicts response to combination of anti-EGFR and anti-PD-L1 therapy in lung cancer patients.**
F. Morgillo¹, M. Fasano¹, C.M. Della Corte¹, R. Di Liello¹, A. Morabito², V. Sforza², F. Sparano¹, M.L. Iacovino¹, F. Paragliola¹, F. Ciardiello¹, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²Istituto dei tumori "G. Pascale", naples, IT
- 12:45 - 12:45 **42TiP - Evaluation of blood tumor mutation burden for improved efficacy of atezolizumab in 2L+ non-small cell lung cancer**
I.-J. Oh¹, H.-J. Cho¹, J.C. Lee², S.Y. Lee³, S.Y. Lee⁴, J.E. Lee⁵, S.-H. Yoon⁶, ¹Chonnam National University Hwasun Hospital, Hwasun, KR, ²Asan Medical Center, University of Ulsan, College of Medicine, Seoul, KR, ³Korea University Guro Hospital, Seoul, KR, ⁴Kyungpook National University, Daegu, KR, ⁵Chungnam National University Hospital, Daejeon, KR, ⁶Pusan National University Yangsan Hospital, Yangsan, KR
- 12:45 - 12:45 **Prevention, Early detection, Epidemiology, Tobacco control**



- 12:45 - 12:45 **45P - DNA methyltransferase 3B -149 and -579 genetic polymorphisms modulates the risk of lung cancer elicited by smoking**
C.-C. Huang¹, C.-Y. Lai², C.-H. Tsai³, J.-Y. Wang², C.-C. Chen¹, R.-H. Wong¹, ¹Chung Shan Medical University Hospital Da-Ching, Taichung City, TW, ²Cheng-Ching General Hospital, Taichung City, TW, ³Tungs' Taichung MetroHarbor Hospital, Taichung City, TW
- 12:45 - 12:45 **46P - Lung cancer risk in solid organ transplant recipients: a Meta-analysis**
F. Ge¹, R. Wang¹, Z. Huo¹, Y. Wen¹, C.C. Li², H. Liang², Y. Jiang¹, Z. Su¹, W. Lin¹, J. He², W. Liang², ¹Guangzhou Medical University, Guangzhou, CN, ²The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN
- 12:45 - 12:45 **47P - Family socioeconomic position and lung cancer risk: a meta-analysis plus Mendelian randomization study**
R. Wang¹, Z. Huo¹, F. Ge¹, Y. Wen¹, Y. Jiang¹, Z. Su¹, C.C. Li², H. Liang², W. Lin¹, J. Li², J. He², W. Liang², ¹Guangzhou Medical University, Guangzhou, CN, ²The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN
- 12:45 - 12:45 **48P - Analysis of risk factors for lung cancer among nonsmoking women in South Korea**
C.K. Park¹, J.Y. Hur², S.J. Kim³, ¹The Catholic University of Korea - College of Medicine - Yeouido St. Mary's Hospital, Seoul, KR, ²Lung Cancer Center, Konkuk University Medical Center, Seoul, KR, ³Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, KR
- 12:45 - 12:45 **49P - Gender differences in the combined effects of smoking, green tea consumption, and NF-κB1 genotypes on Taiwanese lung cancer**
R.-H. Wong¹, C.-C. Huang¹, Y.-T. Chen², Y.-H. He³, C.-Y. Lai⁴, C.-H. Tsai⁵, C.-C. Chen¹, ¹Chung Shan Medical University Hospital Da-Ching, Taichung City, TW, ²Chung Shan Medical University Hospital Da-Ching, Taichung, TW, ³China Medical University Hospital, Taichung, TW, ⁴Cheng-Ching General Hospital, Taichung City, TW, ⁵Tungs' Taichung MetroHarbor Hospital, Taichung City, TW
- 12:45 - 12:45 **50P - Effect of Current Treatment Evolution in Advanced NSCLC on Overall Survival in the Real World**
A. Shokoohi, Z. Al-Hashami, S. Moore, A. Pender, S. Wong, Y. Wang, B. Leung, J. Wu, C. Ho, BC Cancer Agency - Vancouver, Vancouver, CA
- 12:45 - 12:45 **51P - Improvement in Lung Cancer Survival: 6-year Survival Analysis of Patients Diagnosed between 2011 and 2016 in Hungary**
K. Bogos¹, Z. Kiss², G. Székelyné Dr. Galffy³, L. Tamási⁴, G. Ostoros¹, V. Müller⁴, A. Daniel², A. Vastag², Z. Nagy-Erdei², Z. Polanyi⁵, Z. Vokó⁴, B. Nagy⁴, K. Horvath², G. Rokszin⁶, Z. Abonyi-Tóth⁶, N. Bittner⁷, J. Moldvay⁸, ¹OKTPI-Korányi National Institute for Tuberculosis and Pulmonology, Budapest, HU, ²MSD Pharma Hungary Kft., Budapest, HU, ³Pest County Hospital of Pulmonology, Torokbalint, HU, ⁴Semmelweis University, Budapest, HU, ⁵MSD Hungary, Budapest, HU, ⁶RxTarget, Szolnok, HU, ⁷DE KK Tudogyogyaszati Klinika, Debrecen, HU, ⁸Semmelweis University, 2nd Dept. of Internal Medicine, Budapest, HU



- 12:45 - 12:45 **52P - Antibiotic use directly prior to a lung cancer diagnosis: A population-based study**
L. Löfling¹, S. Bahmanyar², H. Kieler², M. Lambe², G. Wagenius³, ¹Karolinska Institute, Stockholm, SE, ²Karolinska Institutet, Solna, SE, ³Karolinska University Hospital, Solna, SE
- 12:45 - 12:45 **53P - Comparison of comorbidity scores in a cohort of hospitalized lung cancer patients**
H. Pluchart¹, S. Bailly², S. Chanoine³, M. Giaj Levra⁴, D. Moro-Sibilot³, P. Bedouch³, A.C. Toffart⁵, ¹CHU Grenoble Alpes - Site Nord (La Tronche), La Tronche, FR, ²Univ. Grenoble Alpes, INSERM U1042, HP2, Grenoble, FR, ³CHU de Grenoble, Hopital Michallon, La Tronche, FR, ⁴CHU Grenoble Alpes - Site Nord La Tronche, La Tronche, FR, ⁵CHU de Grenoble-Alpes- Le site nord à La Tronche - Hopital Michallon, La Tronche, FR
- 12:45 - 12:45 **54P - Correlation between coronary heart disease and risk of lung cancer: a case control study and a mendelian randomization**
J. Li¹, C.C. Li², S. Xiong², B. Cheng², J. He³, W. Liang², ¹State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, CN, ²The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ³The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China, Guangzhou, CN
- 12:45 - 12:45 **55P - Prevalence of lung cancer in patients with atherosclerotic peripheral arterial disease: a meta-analysis of literature data**
F. Bintein¹, A. Yannoutsos¹, G. Chatellier², M. Fontaine³, D. Damotte⁴, P. Paterlini-Bréchet⁴, G. Meyer⁵, V. Duchatelle¹, V. Marini¹, K.-L. Schwering³, C. Labrousse¹, H. Beaussier¹, M. Zins¹, S. Salmeron¹, J.P. Lajonchère¹, P. Priollet¹, J. Emmerich¹, J. Trédaniel¹, ¹Hopital St. Joseph, Paris, FR, ²Hopital Européen Georges Pompidou, Paris, FR, ³Université Paris XIII, Villetaneuse, FR, ⁴Université Paris Descartes, Paris, FR, ⁵Hopital European George Pompidou, Paris, FR
- 12:45 - 12:45 **56P - Association Between Use of Aspirin and Risk of Lung Cancer: Results from Pooled Cohorts and Mendelian Randomization Analyses**
Y. Jiang¹, Z. Su², R. Wang², C.C. Li¹, J. He¹, W. Liang¹, ¹The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ²Guangzhou Medical University, Guangzhou, CN
- 12:45 - 12:45 **57P - Mendelian Randomization Study of Psoriasis and Risk of Lung Cancer**
H. Peng¹, X. Wu², C.C. Li¹, Y. Wen², H. Liang¹, W. Liang¹, J. He¹, ¹The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ²Guangzhou Medical University, Guangzhou, CN
- 12:45 - 12:45 **58P - Acute Radiation-induced Esophagitis as an Early Predictor of Radiation-induced Pneumonitis in Thoracic Radiation**
W. Tang¹, X. Li², X. Sun², J. Yu², P. Xie², ¹Shandong Cancer Hospital Affiliated to



Shandong University, Jinan, CN, 2Shandong cancer hospital, Jinan, CN

- 12:45 - 12:45 **59P - Mendelian Randomization Study of Scleroderma and Risk of Lung Cancer**
H. Peng¹, X. Wu², C.C. Li¹, Y. Wen², H. Liang¹, W. Liang¹, J. He¹, ¹The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ²Guangzhou Medical University, Guangzhou, CN
- 12:45 - 12:45 **Imaging and staging**
- 12:45 - 12:45 **60P - Quantitative image analysis to compare anatomical primary tumor location for surgical and non-surgical treatment regimens for locally advanced NSCLC (SAKK 16/00)**
D. Vuong¹, M. Bogowicz², J. Unkelbach³, S. Hillinger², S. Thierstein⁴, E. Eboulet⁵, S. Peters⁶, M. Pless⁷, M. Guckenberger⁸, S. Tanadini-Lang², ¹University Hospital Zürich, Zurich, CH, ²University Hospital Zurich and University Zurich, Zurich, CH, ³University Hospital Zurich, Zurich, CH, ⁴Swiss Group for Clinical Cancer Research (SAKK), Bern, CH, ⁵SAKK coordinating center, berne, CH, ⁶Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ⁷Kantonsspital Winterthur, Winterthur, CH, ⁸Universitätsspital Zürich, Zürich, CH
- 12:45 - 12:45 **61P - Microenvironment stromal fibro-blast (ACTINIUM TAGGED FAP)imaging Vs. Metabolic Glucose(FDG) imaging, variations in contouring for chemo-radiotherapy in locally advanced or metastatic lung carcinoma.**
G. Lohith¹, K. Kallur¹, K. Sekar², V. Kumar², A. Kesari¹, R. Krishnappa¹, P. Ramachandra¹, B.S. Ajai Kumar², M. Kumar¹, S. Patil², S. Swamy¹, I. Desai¹, P. Sinha¹, M. Senapati¹, S. Bhattacharjee¹, ¹HCG Bangalore Institute of Oncology Speciality Centre, Bangalore, IN, ²HCG Bangalore Institute of Oncology Speciality Centre, bengaluru, IN
- 12:45 - 12:45 **62P - Role of EBUS-TBNA and EUS-FNA in mediastinal lymph nodes biopsies for lung cancer staging: a single-centre experience**
F.T. Gallina, D. Forcella, D. Assisi, F. Pierconti, E. Melis, E. Mercadante, G. Alessandrini, L. Mosillo, V. Cerasoli, F. Corzani, F. Facciolo, IRCCS Regina Elena National Cancer Institute (IRE), Rome, IT
- 12:45 - 12:45 **63P - The Role of Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA) in the Diagnosis of Large Cell Neuroendocrine Carcinoma (LCNEC)**
B. Teng¹, D. Rana¹, D. Shelton¹, N. Narine¹, H. Al-Najjar², ¹Central Manchester University Hospitals NHS Foundation Trust, Manchester, GB, ²Wythenshawe Hospital-South Manchester University Hospitals Trust, Manchester, GB
- 12:45 - 12:45 **64P - MRI Radiogenomic prediction of EGFR and ALK molecular alterations in NSCLC brain metastases among Indian population : A potential non invasive problem solving tool.**
S. Wadhwa¹, M. Malhotra², K. Prabhash¹, A. Mahajan¹, ¹Tata Memorial Hospital, Mumbai, IN, ²TATA MEMEORIAL HOSPITAL, Mumbai, IN



- 12:45 - 12:45 **65P - Radiomics Signature of de novo Symptomatic Brain Metastases from Lung Cancer: MR Imaging Biomarker to Predict EGFR Status**
Y. Li, L. Tan, H.Q. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG
- 12:45 - 12:45 **SCLC**
- 12:45 - 12:45 **68P - Small cell lung cancer derived exosomal miR-375-3p induces vascular permeability and promotes metastasis by targeting Claudin-1**
S. Mao¹, Z. Lu², S. Zheng², G. Zhang², N. Sun², J. He², ¹Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN, ²National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN
- 12:45 - 12:45 **69P - Exosomal proteins as potential diagnostic biomarkers in Small Cell Lung Cancer**
S. Pedersen¹, N. Malin², B. Honoré³, W.M. Szejniuk¹, S.R. Kristensen¹, U. Falkmer¹, ¹Aalborg Universitetshospital - Region Nordjylland, Aalborg, DK, ²Aalborg University, Aalborg, DK, ³Aarhus university, Aarhus C, DK
- 12:45 - 12:45 **70P - Associations between radiotherapy protocol variations and outcome in the CONVERT trial**
R. Mir¹, N. Groom², H. Mistry³, E. Wilson⁴, C. Faivre-Finn⁵, ¹Mount Vernon Cancer Centre - East and North Herts NHS Trust, Northwood, GB, ²National Radiotherapy Trials Quality Assurance Group, Northwood, GB, ³Department of Radiotherapy Related Research, Manchester, GB, ⁴Department of Radiotherapy, London, GB, ⁵The Christie NHS Foundation Trust, Manchester, GB
- 12:45 - 12:45 **71P - Outcome and toxicity of reirradiation for locally recurrent small cell lung cancer (SCLC) - a multicenter study**
L. Käsmann¹, S. Janssen², A. Baschnagel³, T. Kruser⁴, H. Harada⁵, M. Aktan⁶, D. Rades⁷, ¹Ludwig Maximilians University - Grosshadern, Munich, DE, ²University of Luebeck, Luebeck, DE, ³University of Wisconsin School of Medicine and Public Health, Madison, US, ⁴Feinberg School of Medicine, Chicago, US, ⁵Shizuoka Cancer Center, Shizuoka, JP, ⁶Necmettin Erbakan University, Konya, TR, ⁷University SH.-Lübeck, Lübeck, DE
- 12:45 - 12:45 **72P - Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer : a retrospective study**
Y. Lei¹, H. Feng¹, H. Qiang¹, Y. Zhang¹, J. Qian², Q. Chang¹, R. Zhong², X. Fan¹, T. Chu², ¹Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, ²Shanghai Chest Hospital, Shanghai, CN
- 12:45 - 12:45 **73P - Evaluation of Lung Immune Scores for Prediction of Survival in limited stage small cell lung cancer (LS-SCLC)**
L. Schnöller¹, L. Käsmann², J. Taugner³, C. Eze³, O. Roengvoraphoj², F. Manapov²,



¹University Hospital (LMU), Munich, DE, ²Ludwig Maximilians University - Grosshadern, Munich, DE, ³LMU Klinikum der Universität München, Munich, DE

12:45 - 12:45 **74P - French real world study on patient characteristics and treatment strategies in first line of extensive stage small cell lung cancer (ES SCLC)**

D. Debieuvre¹, C. Dayen², A. Dixmier³, S. Gally⁴, W. Greenwood⁴, L. Falchero⁵, ¹Hopital Emile Muller, Mulhouse, FR, ²Clinique de l'Europe, Amiens, FR, ³C.H.R. Orleans - La Source, Orleans, FR, ⁴Roche S.A.S, Boulogne-Billancourt, FR, ⁵Hospital Center De Villefranche-Sur-Saône, Gleizé, FR

12:45 - 12:45 **75P - Analysis of first-line chemotherapy in ED-SCLC; A Japanese single center retrospective study.**

H. Furukawa¹, Y. Okuma¹, H. Horinouchi², Y. Goto¹, T. Yoshida¹, Y. Shinno¹, N. Yamamoto¹, Y. Ohe², ¹National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP, ²National Cancer Center Hospital, Tokyo, JP

12:45 - 12:45 **76P - Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients : a multicenter, single arm, phase II clinical trial**

Z. He¹, C. Xu¹, G. Chen², J. Wang³, X. Zhang⁴, P. Wang⁵, T. Ma⁶, Y. Zhang⁷, C. Tian⁸, Y. Chen⁹, M. Zou¹⁰, Y. Han¹¹, L. Wang¹, S. Ma¹, H. Chen¹, Y. Wu¹, X. Wu¹, S. Yang¹, Y. Gao¹, Q. Wang¹, ¹Henan Cancer Hospital, Zhengzhou, CN, ²First People's Hospital of Shangqiu, Shangqiu, CN, ³Anyang Tumor Hospital, Anyang, CN, ⁴The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁵Xuchang Central Hospital, Xvchang, CN, ⁶Luohe Central Hospital, Luohe, CN, ⁷Zhoukou Hospital of Traditional Chinese Medicine, Zhoukou, CN, ⁸Sanmenxia Central Hospital, Sanmenxia, CN, ⁹Zhumadian Central Hospital, Zhumadian, CN, ¹⁰The Second People's Hospital of Jiaozuo, Jiaozuo, CN, ¹¹Jiyuan Shi People's Hospital, Jiyuan, CN

12:45 - 12:45 **77P - Gemcitabine plus Irinotecan (Gem-Iri) as an active chemotherapy (chemo) treatment in Small Cell Lung Cancer (SCLC) patients (p).**

N. Lopez Zurita¹, C. Ejarque Martínez², S. Soriano², J. Giner², J. Cabrera Romero², I. Macias Declara², E. Dalmau Portulas¹, Y. Garcia Garcia¹, L. Vila Martinez², ¹Parc Tauli Hospital Universitari, Sabadell, ES, ²Hospital de Sabadell Corporacis Parc Tauli, Sabadell, ES

12:45 - 12:45 **78P - Survival analysis of extensive stage small cell lung cancer treated with first line platinum doublet**

S. Kumaravelu, L. Kvs, S.K. K, Madras Medical College, Chennai, IN

12:45 - 12:45 **79P - Limited disease small cell lung cancer (LD-SCLC) treatment (Tx) and survival: a REAL-Oncology (UK) analysis from the I-O Optimise initiative**

M. Snee¹, S. Cheeseman², M. Thompson², M. Riaz³, R. Bowman², W. Sopwith³, L. Lacoïn⁴, C. Chaib⁵, A. Juarez-Garcia⁶, M. Daumont⁴, J. Penrod⁷, J. O'Donnell⁷, G. Hall², ¹St. James's University Hospital - Leeds Teaching Hospitals NHS Trust, Leeds, GB, ²The Leeds Teaching Hospitals NHS Trust, Leeds, GB, ³IQVIA, London, GB, ⁴Bristol-Myers Squibb, Braine-L'Alleud, BE, ⁵Bristol-Myers Squibb, Madrid, ES, ⁶Bristol-Myers Squibb, Uxbridge, GB, ⁷Bristol-Myers Squibb, Princeton, US



- 12:45 - 12:45 **80P - The Ulysses Project: an Italian Survey on caregiver's and physicians' unmet needs in Small Cell Lung Cancer (SCLC).**
M. Bungaro¹, M.V. Pacchiana¹, C. Paratore¹, S. Vallone², R. De Luca³, M. Gianetta¹, D. Grosso⁴, A. Mastrandrea⁵, R. Palmieri⁶, I. Pellerito³, F. Romito⁵, S. Serpentine⁴, S. Novello⁷, ¹Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, ²LuCE, Bern, CH, ³University Hospital Polyclinic "Paolo Giaccone", Palermo, IT, ⁴Veneto Institute of Oncology IOV - IRCCS, Padova, IT, ⁵IRCCS Istituto Tumori "Giovanni Paolo II", Bari, IT, ⁶Foundation 'Policlinico Universitario A. Gemelli', Università Cattolica del Sacro Cuore, Roma, IT, ⁷Università Degli Studi Di Torino - Orbassano, Orbassano, IT
- 12:45 - 12:45 **Early stage NSCLC**
- 12:45 - 12:45 **81P - Identification of significant genes with poor prognosis in pathologic stage-I lung adenocarcinoma**
Y. Deng¹, X. Chen², W. Zhu², J. Lu², R. Zhou³, ¹First Affiliated Hospital of Fujian Medical University, Fuzhou, CN, ²Fujian Cancer Hospital, Fuzhou, CN, ³School of Basic Medical Sciences, Fujian Medical University, Fuzhou, CN
- 12:45 - 12:45 **82P - Early outcome, mortality and major morbidity after lung cancer surgery for primary carcinoma**
F. Gradica¹, L. Lisha², D. Argjiri², A. Cani², F. Kokici², D. Xhemalaj¹, I. Avdiu³, F. Gradica⁴, A. Ymeri³, F. Gradica⁴, A. Lala⁴, A. Vyshka², E. Shima², ¹University Hospital of Lung Disease "Shefqet Ndroqi", Tirana, AL, ²University Hospital of Lung Disease "Shefqet Ndroqi", Tirane, AL, ³University Hospital "Mother Theresa", Tirane, AL, ⁴Public Pharmacy Service, Tirane, AL
- 12:45 - 12:45 **84P - Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations**
W. Liang¹, Q. He², C.C. Li¹, H. Liang¹, B. Cheng¹, J. He², ¹The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ²The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China, Guangzhou, CN
- 12:45 - 12:45 **85P - The Efficacy of EGFR-TKIs on Ground-glass Lesions in Early-stage Multiple Primary Lung Cancer**
B. Cheng, C.C. Li, Y. Zhao, J. Li, S. Xiong, H. Liang, J. Liu, W. Liang, J. He, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN
- 12:45 - 12:45 **87P - Decision-making in Management of Small-sized, High Malignancy Probability Pulmonary Nodules: A Population-based Study of Stage IA NSCLC ≤ 8mm**
S. Jianfei, Taizhou Hospital of Zhejiang Province, Taizhou, CN



- 12:45 - 12:45 **89P - Numbers and Stations: Impact of Examined Lymph Node on Precise Staging and Survival of Radiologically Pure-Solid Lung Cancer**
D. Chen¹, Y. Mao², J. Wen³, J. Shu⁴, F. Ye⁵, Y. Chen⁶, C. Chen¹, ¹Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN, ²Suzhou Kowloon Hospital, Suzhou, CN, ³Shanghai Cancer Center, Shanghai, CN, ⁴Taicang Affiliated Hospital of Soochow University, Taicang, CN, ⁵Hai'an Hospital Affiliated to Nantong University, Hai'an, CN, ⁶The Second Affiliated Hospital of Soochow University, Suzhou, CN
- 12:45 - 12:45 **90P - The CT appearance pattern of radiation-induced lung injury and tumor recurrence after stereotactic body radiation therapy in early stage non-small cell lung cancer**
Q. Li, Y. Xu, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, CN
- 12:45 - 12:45 **91P - Volumetric-modulated-arc-therapy (VMAT) based Stereotactic body radiation therapy (SBRT) in early stage NSCLC: outcomes and toxicities**
E. Martin Garcia, Hospital Universitari i Politècnic La Fe, Valencia, ES
- 12:45 - 12:45 **92P - Efficacy, Safety and Toxicity of Central SBRT in Early Stage NSCLC Patients: A Single Centre Retrospective Study**
Y. Xiao-Shuai¹, Y.-Y. Zhu¹, X.-J. Sun², Y.-P. Xu¹, ¹Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN, ²Cancer Hospital, University of Chinese Academy of Sciences, Hangzhou, CN
- 12:45 - 12:45 **93P - Acute toxicity of SBRT to centrally located lesion of the lung: a multicentric retrospective analysis**
M. Mariotti¹, P. Borghetti², N. Giaj-Levra³, L. Rubino⁴, L. Frassinelli⁴, G. Costantino², M.L. Bonù², M. Perna⁵, V. Salvestrini⁵, F. Alongi³, F. Lohr⁴, V. Scotti⁵, A. Bruni⁴, ¹AIIAO - Associazione Italiana Infermieri di Area Oncologia, Firenze, IT, ²ASST Spedali Civili and University of Brescia, BRESCIA, IT, ³IRCCS Sacro Cuore Don Calabria Hospital, VERONA, IT, ⁴University Hospital "Policlinico of Modena", MODENA, IT, ⁵Careggi University Hospital, FLORENCE, IT
- 12:45 - 12:45 **94P - Correlating clinical variables with local control (LC), progression free survival (PFS) and overall survival (OS) in patients with early stage inoperable lung cancers treated with Stereotactic Ablative Radiotherapy (SABR). A retrospective analysis of the UK's largest cohort**
N. Hatton¹, A. Saha², M. Beasley¹, K. Clarke¹, P. Jain¹, M. Teo¹, P. Murray¹, J. Lilley¹, P. Dickinson¹, K. Franks³, ¹St. James's University Hospital - Leeds Teaching Hospitals NHS Trust, Leeds, GB, ²Apollo Gleneagles Cancer Hospital Kolkata, Kolkata, IN, ³St. James's University Hospital Leeds, Leeds, GB
- 12:45 - 12:45 **95P - SABR for medically inoperable early stage NSCLC: Long term outcomes of 417 patients treated in a non-academic cancer centre**
C. Peedell¹, A. Wood², E. Aynsley², G. Kumar², S. Masinghe², M. Anderson², C. Huntley², J. Green², A. Blower², J. Veeratterapillay², K. Burke², ¹The James Cook University Hospital - South Tees Hospitals NHS Foundation Trust, Middlesbrough, GB, ²James Cook



University Hospital, Middlesbrough, GB

- 12:45 - 12:45 **96P - Prognostic value of preoperative blood markers in surgically treated patients with I-II stages of non-small-cell lung cancer (NSCLC)**
I. Zemtsova¹, A. Petrov¹, M. Atiukov², O. Zhemchugova¹, P. Yablonskii¹, ¹SPSU - St. Petersburg State University, Saint-Petersburg, RU, ²City multidisciplinary hospital 2, Saint-Petersburg, RU
- 12:45 - 12:45 **97P - The clinical value of CT guidance Hook-wire positioning thoracoscopic surgery for ground-glass opacity lung nodules**
H. Chen¹, X. Li¹, G. Lan¹, Z. Zhai¹, L. Huang¹, W. Wang², C. Xu³, Y. Zhu¹, K. Du¹, M. Fang², ¹Zhejiang Rongjun Hospital, Jiaxing, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN
- 12:45 - 12:45 **98P - Surgically resected superior sulcus (SS) non-small cell lung cancer (NSCLC) after induction chemo (C)- and radiotherapy (R): a focus on the immune microenvironment (IM)**
A. Pavan¹, F. Fortarezza², F. Pezzuto², R. Polverosi³, L. Evangelista⁴, S. Frega⁵, L. Bonanno⁵, V. Guarneri⁵, F. Rea⁶, P.F. Conte⁵, F. Calabrese², G. Pasello⁵, ¹IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ²Pathology Unit, Padova, IT, ³Istituto Diagnostico Antoniano-Affidea, Padova, IT, ⁴University of Padova, Padova, IT, ⁵Istituto Oncologico Veneto IRCCS, Padova, IT, ⁶Thoracic Surgery Unit, Padova, IT
- 12:45 - 12:45 **99P - Non-intubated spontaneous ventilation VATS in second surgery for multiple primary lung cancer: a propensity score matching study**
K. Xu¹, H. Liang², W. Cai², Y. Huang², F. Cui², J. Liu², J. He³, ¹The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ²The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ³The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China, Guangzhou, CN
- 12:45 - 12:45 **100P - Changes in pulmonary function in lung cancer patients after video-assisted thoracic surgery**
S.J. Kim¹, Y.J. Lee², J.S. Park², Y.-J. Cho², S. Cho², H.I. Yoon², K. Kim², J.H. Lee², S. Jheon², C.-T. Lee², ¹Sheikh Khalifa Specialty Hospital (SKSH), Ras al Khaimah, AE, ²Seoul National University Bundang Hospital, Gyeonggi-do, KR
- 12:45 - 12:45 **101TiP - CANOPY-N: A Phase II Study of Canakinumab (CAN) or Pembrolizumab (PEM) as Monotherapy or in Combination as Neoadjuvant Therapy in Patients (Pts) with Surgically Resected (Stage IB-III A) Non-Small Cell Lung Cancer (NSCLC)**
P. Garrido Lopez¹, T. Mok², E. Kim³, C. Arslan⁴, J.-L. Pujol⁵, Y. Song⁶, C. Blin⁷, V. Rodrik-Outmezguine⁶, B. Mookerjee⁶, V. Passos⁶, J. Lee⁸, ¹Hospital Universitario Ramon y Cajal, Madrid, ES, ²Chinese University of Hong Kong, Hong Kong, HK, ³Levine Cancer Institute, NC, US, ⁴Izmir Medical Park Hospital Izmir and Bahcesehir University Medicine Faculty, Istanbul, TR, ⁵Hospital Arnaud de Villeneuve, Montpellier, FR, ⁶Novartis Pharmaceuticals Corporation, East Hanover, US, ⁷Novartis Pharma AG, Basel, CH,



⁸University of California, Los Angeles, US

12:45 - 12:45 **Locally advanced NSCLC**

12:45 - 12:45 **103P - Exploring quantitative biomarkers from different tumor volumes for radiomics in lung cancer**

S. Ramella¹, R. D'Angelillo², M. Fiore³, E. Ippolito⁴, N. D'Amico⁴, E. Cordelli⁴, R. Sicilia⁴, P. Soda⁴, ¹Campus Bio-Medico di Roma, Roma, IT, ²University of Rome Tor Vergata, Rome, IT, ³Campus Bio-Medico di Roma, Rome, IT, ⁴campus Bio-Medico di Roma, Rome, IT

12:45 - 12:45 **104P - Neoadjuvant chemotherapy and avelumab in early stage resectable non-small cell lung cancer**

A. Tfayli¹, M. Al Assaad¹, G. Fakhri¹, R. Akel¹, H. Atwi¹, H. Ghanem², F. El Karak³, F. Farhat⁴, K. Al Rabi⁵, P. Sfeir¹, Z. Mansour⁶, H. Assi¹, M. Haidar¹, A. Abi Ghanem¹, I. Khalifeh¹, F. Boulos¹, R. Mahfouz¹, B. Youssef¹, Y. Zeidan¹, R. Bajjiny¹, ¹AUBMC - American University of Beirut Medical Center, Beirut, LB, ²Lebanese american university medical center, Beirut, LB, ³Bellevue Medical Center, Beirut, LB, ⁴Hammoud Hospital, Beirut, LB, ⁵King Hussein Medical Center, Amman, JO, ⁶Lebanese Geitawi University Medical Center, Beirut, LB

12:45 - 12:45 **105P - Neoadjuvant anti-PD-1 immunotherapy plus chemotherapy in patients with stage III non-small cell lung cancer: A real-world, unicentric, retrospective analysis**

H. Deng, H. Liang, J. Liu, J. Li, S. Xiong, Y. Zhong, Q. Ai, W. Lu, C.C. Li, Y. Zhao, B. Cheng, T. Xing, J. He, W. Liang, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN

12:45 - 12:45 **106P - Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German compassionate use program (CUP)**

M. Faehling¹, S. Birgit¹, C. Schumann², P. Christopoulos³, P. Hoffknecht⁴, J. Alt⁵, M. Horn⁶, S. Eisenmann⁷, A. Schlenska-Lange⁸, S.P. Aries⁹, W. Eberhardt¹⁰, P. Schütt¹¹, F. Steger¹², T. Durvalumab-Cup Germany Consortium¹, D.C. Christoph¹⁰, ¹Klinikum Esslingen, Esslingen, DE, ²Klinikum Kempten-Oberallgaeu gGmbH, Kempten, DE, ³Thoraxklinik Heidelberg, Heidelberg, DE, ⁴Niels Stensen Kliniken, Franziskus Hospital Harderberg, Georgsmarienhütte, DE, ⁵Universitätsmedizin Mainz, Mainz, DE, ⁶Krankenhaus Grosshansdorf, Grosshansdorf, DE, ⁷Universitätsklinikum Halle, Halle, DE, ⁸Krankenhaus Barmherzige Brüder, Regensburg, DE, ⁹Elbpneumologie, Hamburg, DE, ¹⁰University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ¹¹Onkologische Schwerpunktpraxis, Gütersloh, DE, ¹²Uniklinik Regensburg, Regensburg, DE

12:45 - 12:45 **107P - Durvalumab after DART-bid compared to conventionally fractionated chemo-radiotherapy in NSCLC stage III: results on acute pneumonitis**

F. Zehentmayr¹, M. Hochmair², P. Feurstein³, F. Jordan⁴, P. Porsch⁵, H. Fabikan⁶, C. Weinlinger⁶, B. Grambozov¹, B. Lamprecht⁷, O. Burghuber², F. Sedlmayer¹, M. Studnicka¹, R. Wass¹, ¹Landeskrankenhaus Salzburg - Universitätsklinikum der PMU,,



Salzburg, AT, ²Otto Wagner Spital, Vienna, AT, ³Wilhelminenspital, Vienna, AT, ⁴University Clinic Salzburg, Salzburg, AT, ⁵Landeskrankenhaus Salzburg - Universitätsklinikum der PMU, Salzburg, AT, ⁶Krankenhaus Nord, Vienna, AT, ⁷Kepler University Hospital, Linz, AT

12:45 - 12:45

108P - The role of different chemotherapy protocols for concurrent chemoradiation in locally advanced NSCLC in the PET Plan trial

E. Gkika¹, T. Schimek-Jasch¹, S. Kremp², M. Tosch³, T. Herr⁴, S.M. Eschmann⁵, Y.-P. Bultel⁶, P. Hass⁷, J. Fleckenstein⁸, A. Thieme⁹, M. Stockinger¹⁰, K. Dieckmann¹¹, S. Adebahr¹², J. König¹³, H.C. Rischke¹⁴, S. Lenz¹⁵, C. Broichhagen¹⁵, H. Binder¹⁵, A.-L. Grosu¹⁶, U. Nestle¹⁷, ¹University Medical Center Freiburg, Freiburg im Breisgau, DE, ²Saarland University Medical Center and Faculty of Medicine, Department of Radiotherapy and Radiation Oncology, Homburg/Saar, Germany, Homburg/Saar, DE, ³Helios University Hospital Wuppertal, Department of Nuclear Medicine, Wuppertal, Germany, Wuppertal,, DE, ⁴Marienhospital Stuttgart, Department of Radiation Oncology, Stuttgart, Germany, Stuttgart,, DE, ⁵Marienhospital Stuttgart, Department of Nuclear Medicine, Stuttgart, Germany, Stuttgart,, DE, ⁶Klinikum Mutterhaus der Boromäerinnen, Department of Radiation Oncology, Trier, Germany, Trier,, DE, ⁷University Hospital Magdeburg, Department of Radiation Oncology, Magdeburg, Germany, Magdeburg,, DE, ⁸Saarland University Medical Center and Faculty of Medicine, Department of Radiotherapy and Radiation Oncology, Homburg/Saar, Germany, Homburg/Saar,, DE, ⁹Charité –Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Radiation Oncology, Berlin, Germany, Berlin, DE, ¹⁰University Hospital Mainz, Department of Radiation Oncology, Mainz,, Mainz, DE, ¹¹Medical University of Vienna, Vienna General Hospital, Department of Radiotherapy, Vienna, Austria, Vienna, AT, ¹²Strahlentherapie Freiburg / Klinik für Strahlenheilkunde, Freiburg im Breisgau, DE, ¹³University Hospital of Mainz, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), Mainz, Germany, Mainz, DE, ¹⁴University of Freiburg, Medical Center Faculty of Medicine, Department of Radiation Oncology, Germany, Freiburg im Breisgau, DE, ¹⁵Institut für Medizinische Biometrie und Statistik (IMBI), Freiburg im Breisgau, DE, ¹⁶University of Freiburg, Freiburg, DE, ¹⁷Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg im Breisgau, DE

12:45 - 12:45

109P - Sequential Chemo-radiotherapy for stage III NSCLC: Feasibility of radiotherapy planning in the first 50 patients recruited to the ADSCaN trial

R. Mir¹, R. Simoes², C. Lawless³, E. McCartney³, A. Shaw³, C. Peedell⁴, T. Pope⁵, J. Lester⁶, D. Landau⁷, C. Faivre-Finn⁸, M. Hatton⁹, ¹Mount Vernon Cancer Centre - East and North Herts NHS Trust, Northwood, GB, ²National Radiotherapy Trials Quality Assurance Group, London, GB, ³Cancer Clinical Trials Unit Scotland, Glasgow, GB, ⁴James Cook University Hospital, Middlesborough, GB, ⁵Clatterbridge Cancer Centre, Liverpool, GB, ⁶Velindre Cancer Centre, Cardiff, GB, ⁷Guy's and St Thomas' Hospital, London, GB, ⁸The Christie NHS Foundation Trust, Manchester, GB, ⁹Weston Park Hospital Cancer Research Centre, Sheffield, GB

12:45 - 12:45

110P - Title: Stage III NSCLC patient population for sequential Chemo-radiotherapy: Demographics of the first 54 patients recruited to the ADSCaN trial.



M. Hatton¹, R. Simoes², R. Mir³, C. Lawless⁴, E. McCartney⁴, A. Shaw⁴, C. Peedell⁵, T. Pope⁶, C. Faivre-Finn⁷, ¹Weston Park Hospital Cancer Research Centre, Sheffield, GB, ²National Radiotherapy Trials Quality Assurance Group, London, GB, ³Mount Vernon Cancer Centre - East and North Herts NHS Trust, Northwood, GB, ⁴Cancer Clinical Trials Unit Scotland, Glasgow, GB, ⁵The James Cook University Hospital - South Tees Hospitals NHS Foundation Trust, Middlesbrough, GB, ⁶Clatterbridge Cancer Centre, GB, ⁷The Christie NHS Foundation Trust, Manchester, GB

12:45 - 12:45 **111P - Is there a difference in outcomes following chemoradiotherapy for NSCLC when using Volumetric Arc Therapy?**

L. Karsera¹, P. Jain¹, F. Sun², P. Dickinson¹, K. Franks³, P. Murray¹, K. Clarke¹, M. Teo¹, ¹St. James's University Hospital - Leeds Teaching Hospitals NHS Trust, Leeds, GB, ²Castle Hill Hospital, Cottingham, GB, ³St. James's University Hospital Leeds, Leeds, GB

12:45 - 12:45 **112P - Combination of immune check-point inhibition with definitive chemoradiotherapy significantly improves loco-regional tumor control and survival in patients with inoperable stage III NSCLC**

F. Manapov¹, J. Taugner², L. Kaesmann³, C. Eze², M. Dantes², O. Roengvoraphoj¹, C. Belka⁴, ¹Ludwig Maximilians University - Grosshadern, Munich, DE, ²LMU Klinikum der Universität München, Munich, DE, ³LMU - Ludwig Maximilians University - Grosshadern, Munich, DE, ⁴University of Munich LMU, Munich, DE

12:45 - 12:45 **113P - Re-irradiation for locally recurrent lung cancer: A single center retrospective analysis**

B. Grambozov¹, E. Nussdorfer², J. Kaiser³, C. Gaisberger³, G. Fastner³, R. Wass³, P. Porsch⁴, M. Studnicka³, F. Sedlmayer³, F. Zehentmayr³, ¹Landeskrankenhaus Salzburg, Salzburg, AT, ²Paracelsus Medical University, Salzburg, AT, ³Landeskrankenhaus Salzburg - Universitätsklinikum der PMU, Salzburg, AT, ⁴Landeskrankenhaus Salzburg - Universitätsklinikum der PMU, Salzburg, AT

12:45 - 12:45 **114P - Stereotactic radiotherapy for unresectable locally advanced non-small cell lung cancer: clinical outcomes of a phase II trial**

F. Arcidiacono¹, P. Anselmo¹, M. Casale¹, F. Trippa¹, L. Draghini¹, S. Terenzi¹, A. Di Marzo¹, M. Italiani², S. Fabiani², E. Maranzano², ¹Azienda Ospedaliera Sta Maria, Terni, IT, ²Azienda Ospedaliera Santa Maria, Terni, IT

12:45 - 12:45 **115P - T category with rib invasion of non-small cell lung cancer: a propensity-score matching analysis**

J. Wu¹, Y. She¹, T. Wang¹, J. Deng², M. Zhao¹, C. Chen², ¹Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, CN, ²Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN

12:45 - 12:45 **116P - Report on feasibility and efficacy of Hypo-IGRT in stage IIB-III NSCLC patients with poor PS & diminished lung function**

C. Eze¹, J. Taugner¹, N.-S. Schmidt-Hegemann², O. Roengvoraphoj³, L. Käsmann³, M. Dantes¹, M. Li², C. Belka⁴, F. Manapov³, ¹LMU Klinikum der Universität München, Munich, DE, ²LMU - Ludwig Maximilians University - Grosshadern, Munich, DE, ³Ludwig



Maximilians University - Grosshadern, Munich, DE, ⁴University of Munich LMU, Munich, DE

- 12:45 - 12:45 **117P - Prognostic role of involved lymph node after systematic mediastinal dissection in NSCLC**
V. Marziali, L. Frasca, G. Tacchi, F. Longo, P. Crucitti, UCBM - Università Campus Bio-Medico di Roma, Rome, IT
- 12:45 - 12:45 **118P - Pulmonary function decreases moderately after accelerated high-dose irradiation for NSCLC stage III**
F. Zehentmayr, B. Grambozov, F. Wolf, J. Kaiser, R. Wass, G. Fastner, C. Gaisberger, L. Rettenbacher, M. Studnicka, C. Pirich, F. Sedlmayer, Landeskrankenhaus Salzburg - Universitätsklinikum der PMU,, Salzburg, AT
- 12:45 - 12:45 **119P - Characterization of microbiome in cancerous lung and the contralateral noncancerous lung within lung cancer patients**
M. Zhuo, T. An, C. Zhang, Z. Wang, Peking University Cancer Hospital and Institute, Beijing, CN
- 12:45 - 12:45 **120P - Treatment patterns in non-small cell lung cancer (NSCLC) in Portugal following the introduction of immunotherapy at 2nd line: an IPO-PORTO database analysis (I-O Optimise program)**
M. Soares¹, L. Antunes², J. Oliveira-Gomes², G. Paupério², J. Cardia², P. Redondo², M. Borges², C. Chaib³, L. Lacoïn⁴, F. Grimson⁵, E. Ralphs⁵, R. Munro⁵, M. Daumont⁴, J. Penrod⁶, J. O'Donnell⁶, M.J. Bento², F. R. Gonçalves⁷, ¹Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), Porto, PT, ²Portuguese Oncology Institute of Porto (IPO-Porto), Porto, PT, ³Bristol-Myers Squibb, Madrid, ES, ⁴Bristol-Myers Squibb, Braine-L'Alleud, BE, ⁵IQVIA, London, GB, ⁶Bristol-Myers Squibb, Princeton, US, ⁷Porto University, Porto, PT
- 12:45 - 12:45 **122P - Clinicopathological characteristics and survival analysis for resected pulmonary large-cell neuroendocrine carcinoma.**
Y. Shen, F. Hu, C. Li, J. Xu, R. Zhong, X. Zhang, B. Han, Shanghai Chest Hospital, Shanghai, CN
- 12:45 - 12:45 **123TiP - Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC - the ETOP CHESSTrial.**
M. Guckenberger¹, I. Opitz², U. Dafni³, A. Curioni Fontecedro², A. Scherz⁴, O. Elicin⁵, A. Addeo⁶, J. Aerts⁷, D. Betticher⁸, L. Hendriks⁹, B. Jimenez Munarriz¹⁰, O.J. Juan Vidal¹¹, I.G. Sullivan¹², J. Valdivia Bautista¹³, A.-C. Piguet¹⁴, H. Roschitzki-Voser¹⁴, S. Ehrbar¹, M. Baumgartl¹, S. Peters¹⁵, R.A. Stahel², ¹Universitätsspital Zürich, Zürich, CH, ²University Hospital Zürich, Zurich, CH, ³University of Athens, Athens, GR, ⁴Inselspital - Universitätsklinik für Medizinische Onkologie, Bern, CH, ⁵Inselspital - Universitätsspital Bern, Bern, CH, ⁶Hopitaux Universitaires de Geneve - HUG, Geneva, CH, ⁷Erasmus University Medical Center, Rotterdam, NL, ⁸HFR - Hopital Cantonal, Fribourg, CH, ⁹Maastricht University Medical Center (MUMC), Maastricht, NL, ¹⁰Centro Integral



Oncologico Clara Campal, Madrid, ES, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, ES, ¹²Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹³Hospital Universitario Virgen de las Nieves, Granada, ES, ¹⁴ETOP - European Thoracic Oncology Platform, Bern, CH, ¹⁵Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

12:45 - 12:45 **Advanced NSCLC**

12:45 - 12:45 **132P - Immune characteristics and the value of anti-PD-1 and anti-PD-L1 blockade among Non-Small Cell Lung Cancer patients with EGFR and HER2 Exon 20 insertions**

Y. Fan¹, K. Chen², ¹zhejiang cancer hospital, Hangzhou, CN, ²ZHEJIANG CANCER HOSPITAL, Hangzhou, CN

12:45 - 12:45 **133P - Identification of long-responders and fast-progressors under immunotherapy based on early monitoring of dNLR in advanced NSCLC patients (pts)**

M. Riudavets¹, L. Mezquita², E. Auclin³, F. Blanc-Durand⁴, A. De Giglio⁵, L. Hendriks⁶, R. Ferrara⁷, C. Naltet², P. Lavaud², A. Gazzah², J. Adam², D. Planchard², N. Chaput⁸, C. Caramella², B. Besse², ¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ²Institut Gustave Roussy, Villejuif, FR, ³Hopital European George Pompidou, Paris, FR, ⁴Institut Curie, Paris, FR, ⁵Policlinico S. Orsola-Malpighi, Bologna, IT, ⁶Maastricht University Medical Center (MUMC), Maastricht, NL, ⁷Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁸Gustave Roussy Institut de Cancérologie, Villejuif, FR

12:45 - 12:45 **134P - Characterizing safety of dual immunotherapy, nivolumab (NIVO) + ipilimumab (IPI): understanding and managing select treatment-related adverse events (TRAEs) in CheckMate (CM) 227 Part 1**

L. Paz-Ares¹, A. Pluzanski², R. Bernabe Caro³, K. Hyeong Lee⁴, M. Provencio⁵, E. Carcereny⁶, S. Burgers⁷, A. Alexandru⁸, L. Lupinacci⁹, H. Sakai¹⁰, R. Sangha¹¹, A. Vergnenegre¹², J. De Kerangat Raimbourg¹³, K. Feeney¹⁴, Y. Ohe¹⁵, A. Li¹⁶, F. Nathan¹⁶, S. Ramalingam¹⁷, ¹University Hospital 12 De Octubre, Madrid, ES, ²Centrum Onkologii-Instytut im.M.Sklodowskiej-Curie, Warsaw, PL, ³Hospital Universitario Virgen Del Rocio, Instituto de Biomedicina de Sevilla, Seville, ES, ⁴Chungbuk National University, Chungcheonbuk-do, KR, ⁵Hospital Universitario Puerta de Hierro, Madrid, ES, ⁶Catalan Institute of Oncology - Germans Trias i Pujol Hospital, B-ARGO group, Badalona, ES, ⁷Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, NL, ⁸Institute of Oncology "Prof. Dr. Alexandru Trestioreanu" Bucha, Bucharest, RO, ⁹Hospital Italiano De Buenos Aires, Buenos Aires, AR, ¹⁰Saitama Cancer Center, Saitama, JP, ¹¹Cross Cancer Institute, Edmonton, CA, ¹²Limoges University Hospital, Limoges, FR, ¹³ICO Papin, Angers, FR, ¹⁴St John of God Murdoch Hospital, Perth, AU, ¹⁵National Cancer Center Hospital, Tokyo, JP, ¹⁶Bristol-Myers Squibb, Princeton, US, ¹⁷Winship Cancer Institute, Atlanta, US

12:45 - 12:45 **135P - Bone metastasis reduces immune checkpoint inhibitors monotherapy efficacy in advanced NSCLC patients: A retrospective study**

F. Zhou¹, X. Li¹, C. Su², ¹Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, ²Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN



- 12:45 - 12:45 **136P - Steroid use independently predicts poor outcome in patients with advanced NSCLC and high PD-L1 expression receiving first-line pembrolizumab monotherapy**
- G. Mountzios¹, D. Signorelli², O. Panagiota³, J. Rey Cobo⁴, M. Banini⁵, G. Lo Russo², P. Baxevanos⁶, F. Roila⁷, A. De Toma⁸, G.L. Banna⁹, A. Christopoulou¹⁰, B. Jimenez Munarriz¹¹, A. Collazo Lorduy¹¹, A. Calles Blanco¹², D. Galetta¹³, A. Addeo¹⁴, A. Camerini¹⁵, P. Pizzutillo¹⁶, M. Garassino², G. Metro⁵, ¹University of Athens School of Medicine Clinical Therapeutics, Athens, GR, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ³Attikon University Hospital, Athens, GR, ⁴Geneva University Hospital, Geneva, CH, ⁵Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, IT, ⁶Agios Savvas Regional Cancer Hospital, Athens, GR, ⁷Azienda Ospedaliera Sta Maria, Terni, IT, ⁸Fondazione IRCCS, Istituto Nazionale Tumori di Milano, Milano, IT, ⁹Lincoln County Hospital - United Lincolnshire Hospitals NHS Trust, Lincoln, GB, ¹⁰General Hospital of Patras, Patras, GR, ¹¹Centro Integral Oncologico Clara Campal, Madrid, ES, ¹²Hospital General Universitario Gregorio Marañon, Madrid, ES, ¹³Istituto Tumori Giovanni Paolo II, Bari, IT, ¹⁴Hopitaux Universitaires de Geneve - HUG, Geneva, CH, ¹⁵Ospedale "Versilia", Lido di Camaiore, IT, ¹⁶IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy, Bari, IT
- 12:45 - 12:45 **137P - The prognostic value of early weight loss and changes in body composition in non small cell lung cancer patients treated with second line nivolumab.**
- J. Degens, Academisch Ziekenhuis Maastricht (AZM), Maastricht, NL
- 12:45 - 12:45 **138P - Swiss cost-effectiveness analysis of pembrolizumab alone and in combination with chemotherapy as first-line treatments for patients with metastatic non-small cell lung cancer and high PD-L1**
- M. Barbier¹, E. Pardo², C. Panje³, O. Gautschi², J. Lupatsch⁴, ¹University of Basel - Institute of Pharmaceutical Medicine, Basel, CH, ²Luzerner Kantonsspital, Luzern, CH, ³Kantonsspital St. Gallen, St. Gallen, CH, ⁴Swiss Group for Clinical Cancer Research Coordinating Centre, Bern, CH
- 12:45 - 12:45 **139P - Statin use and survival in non-small cell lung cancer (NSCLC) patients treated with immunocheckpoint inhibitors (ICI)**
- S. Cedres¹, A. Callejo², P. Iranzo², N. Pardo², A. Navarro Mendivil², A. Martinez², N. Saoudi², G. Rodriguez³, V. Monton³, S. Recasens³, R. Gutierrez³, L. Sanchez³, R. Madrenas³, C. Carbonell³, J. Frigola³, R. Amat³, F. Ruiz³, R. Dienstmann¹, E. Felip¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron Institute of Oncology and University Hospital, Barcelona, ES, ³Vall d'Hebron Institute of Oncology, Barcelona, ES
- 12:45 - 12:45 **140P - Severe cholangitis induced by PD-1/L1 inhibitors in non-small cell lung cancer**
- A. Yamamoto¹, H. Horinouchi², Y. Maruki¹, Y. Shinno¹, Y. Okuma¹, T. Yoshida¹, Y. Goto¹, Y. Yatabe², Y. Ohe², ¹National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP, ²National Cancer Center Hospital, Tokyo, JP
- 12:45 - 12:45 **141P - Pretreatment Lung Immune Prognostic Index (LIPI) as biomarker in patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated with**



first line pembrolizumab: preliminary results from a retrospective multicenter analysis.

A. Veccia¹, V. Sforza², E. Vattei³, A. Inno⁴, S. Kinspergher¹, M. Dipasquale¹, C. Carnaghi³, S. Gori⁴, A. Morabito⁵, O. Caffo¹, ¹Ospedale Santa Chiara, Trento, IT, ²Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G Pascale', IRCCS, Napoli, IT, ³Central Hospital, Bolzano, IT, ⁴Ospedale Sacro Cuore - Don Calabria, Negrar, IT, ⁵Istituto Nazionale Tumori, 'Fondazione G Pascale', IRCCS, Napoli, IT

12:45 - 12:45 **143P - Evaluation of combined biomarkers in response to immunotherapy in patients with advanced non-small cell lung cancer**

H. Ramdani¹, M. Falk², S. Schatz², L. Heukamp³, M. Tiemann², E. Schuurin⁴, H. Groen⁴, F. Griesinger⁵, ¹European medical school, Oldenburg, DE, ²Hematopathology Hamburg, Hamburg, DE, ³NEO New Oncology, Cologne, DE, ⁴University Hospital Groningen (UMCG), Groningen, NL, ⁵Pius Hospital, University of Oldenburg, Oldenburg, DE

12:45 - 12:45 **144P - Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated interim results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)**

C. Grohe¹, W. Gleiber², S. Haas³, S. Krüger⁴, H. Mueller-Huesmann⁵, M. Schulze⁶, J. Atz⁷, R. Kaiser⁷, ¹Evangelische Lungenklinik ELK Berlin Chest Hospital, Berlin, DE, ²University Hospital, Goethe University Frankfurt, Frankfurt, DE, ³FEK - Friedrich-Ebert-Krankenhaus, Neumünster, DE, ⁴Florence Nightingale Hospital, Duesseldorf, Düsseldorf, DE, ⁵Bruederkrankenhaus St. Josef, Paderborn, DE, ⁶Ambulante Onkologie Ostsachsen, Zittau, DE, ⁷Boehringer Ingelheim Pharma- Germany, Ingelheim am Rhein, DE

12:45 - 12:45 **145P - Activated NOTCH pathway may be associated with the acquired resistance of ICI therapy in patients with isolated adrenal metastasis**

F. Zhou¹, S. Ren¹, C. Zhou², ¹Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, ²Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN

12:45 - 12:45 **146P - Is first line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2) safe? An interim analysis of the multicenter, single-arm SAKK phase II trial 19/17**

M. Mark¹, P. Froesch², E. Eboulet³, A. Addeo⁴, M. Pless⁵, S. Rothschild⁶, W.-D. Janthur⁷, H. Burmeister⁸, M. Schneider³, I. Metaxas¹, M. Joerger⁹, L. Wannesson De Nicola¹⁰, M. Schwitter¹, N. Baudoux⁴, S. Weindler⁹, C. Biaggi³, M. Frueh⁹, ¹Kantonsspital Graubünden, Chur, CH, ²IOSI Istituto Oncologico Svizzera Italiana, Locarno, CH, ³SAKK coordinating center, berne, CH, ⁴Hopitaux Universitaires de Geneve - HUG, Geneva, CH, ⁵Kantonsspital Winterthur, Winterthur, CH, ⁶Universitatsspital Basel, Basel, CH, ⁷Kantonsspital Aarau, Aarau, CH, ⁸Spital STS AG Onkologiezentrum Thun-Berner Oberland, Thun, CH, ⁹Kantonsspital St. Gallen, St. Gallen, CH, ¹⁰IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH

12:45 - 12:45 **147P - PD-L1 expression and efficacy of immunotherapy in Japanese patients with NSCLC harboring MET exon 14 skipping mutation.**

Y. Kato¹, Y. Watanabe¹, Y. Yamane¹, H. Mizutani¹, F. Kurimoto¹, G. Yamamoto¹, K. Akagi¹,



H. Sakai², ¹Saitama Cancer Center, Saitama, JP, ²Saitama Cancer Center, Ina, JP

- 12:45 - 12:45 **148P - A real-world study on the efficacy of programmed death 1/programmed death ligand 1 inhibitors in metastatic non-small cell lung cancer and exploratory analysis of predictive biomarker**
W. Zhu, L. Yu, M. Cong, Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN
- 12:45 - 12:45 **149P - Clinical factors affecting patients' outcome and baseline NLR, PD-L1 expression and LDH level as indicators for clinical management of advanced PD-L1 \geq 50% non-small cell lung cancer (aNSCLC) treated with first line pembrolizumab**
O. Cantale¹, D. Signorelli², G. Metro³, D. Galetta⁴, G.L. Banna⁵, A. De Toma⁶, M. Banini³, A. Friedlaender⁷, A. Catino⁸, P. Pizzutillo⁹, M. Garassino¹⁰, A. Addeo⁷, ¹University of Catania, Catania, IT, ²Fondazione IRCCS, Istituto Nazionale Tumori di Milano, Milan, IT, ³Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, IT, ⁴IRCCS Istituto Tumori Giovanni Paolo II, Bari, IT, ⁵Lincoln County Hospital - United Lincolnshire Hospitals NHS Trust, Lincoln, GB, ⁶Fondazione IRCCS, Istituto Nazionale Tumori di Milano, Milano, IT, ⁷Hopitaux Universitaires de Geneve - HUG, Geneva, CH, ⁸Istituto Tumori Giovanni Paolo II, Bari, IT, ⁹IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy, Bari, IT, ¹⁰Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
- 12:45 - 12:45 **150P - Meta-analysis of the incidence of hyperprogressive disease in patients with non-small cell lung cancer associated with PD-1/PD-L1 inhibitors**
J.Y. Zhang, H.J. Cui, X. Zhang, W. Shen, C.Y. Sun, K.X. Tan, X.J. Jiang, S.Y. Zheng, J. Li, C.X. Xue, Beijing University of Chinese Medicine, Beijing, CN
- 12:45 - 12:45 **151P - Pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts): Impact of blood-based biomarkers on survival outcomes**
A. Ortega Franco¹, R. Tay², H. Raja³, C. Ackermann⁴, C. Mathew⁵, C. Lindsay⁵, S. Hughes⁵, L. Cove-Smith⁵, P. Taylor⁵, Y. Summers⁵, F. Blackhall⁵, R. Califano⁵, ¹The Clatterbridge Cancer Centre, Liverpool, GB, ²Royal Hobart Hospital, Hobart, AU, ³Luton and Dunstable University Hospital, Luton, GB, ⁴Spital STS AG Onkologiezentrum Thun-Berner Oberland, Thun, CH, ⁵The Christie NHS Foundation Trust, Manchester, GB
- 12:45 - 12:45 **152P - Association between PD-L1 expression and brain metastasis in patients with non-small cell lung cancer and their clinical implications.**
K. Lee¹, Y.J. Choi², J.S. Kim³, S.Y. Lee⁴, E.J. Kang⁴, ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²Korea University Anam Hospital, Seoul, KR, ³Korea University Ansan Hospital, Gyeonggi-do, KR, ⁴Korea University Guro Hospital, Seoul, KR
- 12:45 - 12:45 **153P - Investigation of lung cancer patients receiving immunotherapy with pre-existing chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)**
K. MCGOVERN, N. Seetharamu, Northwell Health Cancer Institute, Lake Success, US



- 12:45 - 12:45 **154P - Role of Immune Checkpoint Inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) with oncogenic mutations**
O.S. Ng¹, C. Kho², M.-K. Ang¹, W.L. Tan¹, R. Kanesvaran¹, G. Lai¹, A. Jain¹, T. Rajasekaran¹, C.K. Toh¹, E.H. Tan¹, D.S.W. Tan¹, D. Lim³, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²National University of Singapore, Singapore, SG, ³National Cancer Centre Singapore, Singapore, SG
- 12:45 - 12:45 **155P - Explore the Efficacy of Immune Checkpoint Inhibitors in the Treatment of Non-small Cell Lung Cancer Patients with Different Genes Mutation**
S.-Y. Zheng¹, H.-J. Cui², ¹Beijing University of Chinese Medicine, Beijing, CN, ²China-Japan Friendship Hospital, Beijing, CN
- 12:45 - 12:45 **156P - A phase I clinical study to investigate the safety, tolerability and pharmacokinetics of PD-1 antibody Camrelizumab (SHR-1210) in patients with solid tumor: the results of Non-small cell lung cancer cohort.**
L. Zhang¹, M. Yuxiang², W. Fang², H. Zhao², Y. Zhang², S. Hong², D. Xu³, ¹State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN, ³Jiangsu Hengrui Medicine Co., Ltd., Shanghai, CN
- 12:45 - 12:45 **157P - Safety and response rate in older patients with lung cancer treated with first-line immunotherapy as monotherapy or in combination with chemotherapy: real world data**
M. Blasi¹, J. Kuon², P. Christopoulos², C. Wiedemann³, H. Grosch³, F. Herth², C.P. Heußel³, A. Stenzinger⁴, M. Thomas², ¹Ospedale San Paolo, Milan, IT, ²Thoraxklinik Heidelberg, Heidelberg, DE, ³Thoraxklinik, Heidelberg, DE, ⁴University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE
- 12:45 - 12:45 **158P - Real word data of advanced non-small cell lung cancer (NSCLC) patients (pts) treated with Immune Checkpoint Inhibitors (ICIs).**
A. Callejo¹, N. Diaz², J.D. Assaf², P. Iranzo², N. Pardo², A. Navarro Mendivil², A. Martinez², S. Cedres³, S. Recasens⁴, R. Gutierrez⁴, R. Madrenas⁴, L. Sanchez⁴, F. Ruiz⁴, R. Dienstmann³, E. Felip³, ¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ²Vall d'Hebron Institute of Oncology and University Hospital, Barcelona, ES, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Vall d'Hebron Institute of Oncology, Barcelona, ES
- 12:45 - 12:45 **159P - Prognostic and predictive value of Neutrophil to Lymphocyte Ratio (N/L) in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy.**
N. Piera Molons, T. Fenollosa Sanz, M.D.C. Gómez Soler, B. Honrubia Peris, P. Llor Rodríguez, J. García Sanchez, J. Garde-Noguera, Hospital Arnau de Vilanova, Valencia, ES
- 12:45 - 12:45 **160P - High metabolic tumor burden on 18F-FDG PET/CT does not exclude patients with advanced NSCLC with high PDL-1 expression from responding to monotherapy with PD-1 immune checkpoint inhibitors**
K. Vekens¹, L. Decoster¹, B. Neyns², ¹UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, ²Vrije Universiteit Brussel-Campus Jette, Brussels, BE



- 12:45 - 12:45 **161P - Preliminary results of fast sequential treatment with direct acting antiviral drugs (DAA) and immune checkpoint inhibitors (ICI) in hepatitis C virus (HCV) positive advanced non-small cell lung cancer (NSCLC) patients**
M. Tagliamento¹, F. Lorenzini², C. Genova³, G. Rossi³, F. Grossi⁴, A. De Maria²,
¹University of Genova, Genova, IT, ²University of Genova, Genova, IT, ³IRCCS Policlinico San Martino Hospital, Genova, IT, ⁴Ospedale Maggiore Policlinico-Fondazione IRCCS Ca' Granda, Milan, IT
- 12:45 - 12:45 **162P - The relation between PD-L1 expression and EGFR mutation before and after the tyrosine kinase inhibitors treatment in NSCLC patients**
H. Liang, Y. Chen, W. Liang, J. He, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN
- 12:45 - 12:45 **163P - Incidence of hyperprogression in non-small-lung cancer patients treated with immunotherapy in VietNam National Cancer Hospital**
A. Dinh, T. Dao, K3 Hospital - Vietnam National Cancer Hospital, Hanoi, VN
- 12:45 - 12:45 **164P - Brigatinib (BRG) vs Crizotinib (CRZ) in the Phase 3 ALTA-1L Trial: Updated Results**
M.R. Garcia Campelo¹, H.R. Kim², M.-J. Ahn³, J.C.-H. Yang⁴, J.-Y. Han⁵, M. Hochmair⁶, K.H. Lee⁷, A. Delmonte⁸, D.-W. Kim⁹, F. Griesinger¹⁰, E. Felip¹¹, R. Califano¹², A. Spira¹³, S. Gettinger¹⁴, M. Tiseo¹⁵, H. Lin¹⁶, Q. Ni¹⁷, P. Zhang¹⁷, S. Popat¹⁸, D.R. Camidge¹⁹,
¹Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ²Yonsei University Severance Hospital, Seoul, KR, ³Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ⁴National Taiwan University Hospital, Taipei city, TW, ⁵National Cancer Center, Goyang, KR, ⁶Otto Wagner Hospital - Respiratory Oncology Unit - Pav Leopold 1, Vienna, AT, ⁷Chungbuk National University Hospital, Cheongju, KR, ⁸IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS S.r.l., Meldola, IT, ⁹Seoul National University Hospital, Seoul, KR, ¹⁰Pius Hospital, University of Oldenburg, Oldenburg, DE, ¹¹Vall d'Hebron University Hospital, Barcelona, ES, ¹²The Christie NHS Foundation Trust, Manchester, GB, ¹³Virginia Cancer Specialist, Fairfax, US, ¹⁴Yale University School of Medicine, New Haven, US, ¹⁵AOU di Parma, Parma, IT, ¹⁶Millennium Pharmaceutical (subsidiary of Takeda Pharmaceutical Company Ltd), Cambridge, US, ¹⁷Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, US, ¹⁸Royal Marsden Hospital NHS Foundation Trust, London, GB, ¹⁹University of Colorado Cancer Center, Aurora, US
- 12:45 - 12:45 **165P - Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer**
A. Drilon¹, S. Kummar², V. Moreno³, J. Patel⁴, U. Lassen⁵, B. Solomon⁶, L. Rosen⁷, S. Leyvraz⁸, D.S.W. Tan⁹, J.A. Reeves¹⁰, N. Brega¹⁰, B.H. Childs¹⁰, A.F. Farago¹¹, ¹Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, US, ²Stanford Cancer Institute, Stanford University, Palo Alto, US, ³START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, ES, ⁴University of Chicago, Chicago, US, ⁵Rigshospitalet, Copenhagen, DK, ⁶Avera Cancer Institute, Sioux Falls, US, ⁷UCLA, Los Angeles, US, ⁸Charité - Universitätsmedizin Berlin, Berlin, DE, ⁹NCCS - National Cancer



Centre Singapore, Singapore, SG, ¹⁰Bayer HealthCare Pharmaceuticals, Whippany, US,
¹¹Massachusetts General Hospital Cancer Center, Boston, US

- 12:45 - 12:45 **166P - RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients (pts) with previously untreated, EGFR-mutated, metastatic NSCLC: Clinical outcomes by EGFR mutation type type**
- K. Nakagawa¹, E. Nadal², E. Garon³, M. Nishio⁴, T. Seto⁵, N. Yamamoto⁶, K. Park⁷, J.-Y. Shih⁸, B. Frimodt-Moller⁹, A.-M. Zimmermann¹⁰, C. Visseren-Grul¹¹, M. Reck¹², ¹Kindai University School of Medicine, Osaka, JP, ²ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ³UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ⁴Cancer Institute Hospital of JFCR, Tokyo, JP, ⁵National Kyushu Cancer Center, Fukuoka, JP, ⁶Wakayama Medical University, Wakayama, JP, ⁷Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ⁸National Taiwan University Hospital, Taipei city, TW, ⁹Eli Lilly, Lyngby, DK, ¹⁰Eli Lilly and Company, Indianapolis, US, ¹¹Eli Lilly Netherlands, Utrecht, NL, ¹²Krankenhaus Grosshansdorf, Grosshansdorf, DE
- 12:45 - 12:45 **167P - Efficacy and safety of 450 mg/d or 600 mg/d ceritinib with food vs. 750 mg/d fasted in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC): Results from ASCEND-8 Asian subgroup analysis**
- B.C. Cho¹, D.-W. Kim², U. Batra³, K. Park⁴, S.-W. Kim⁵, C.-T. Yang⁶, V. Pei Jye⁷, V. Sriuranpong⁸, K.G. Babu⁹, K. Amin¹⁰, W. Zhou¹¹, K. Slimane¹⁰, S. Geater¹², ¹Yonsei Cancer Center Yonsei University, Seoul, KR, ²Seoul National University Hospital, Seoul, KR, ³Rajiv Gandhi Cancer Institute & Research Center, New Delhi, IN, ⁴Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ⁵Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁶Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, TW, ⁷Hospital Umum Sarawak, Kuching, MY, ⁸Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok, TH, ⁹HCG Curie Center of Oncology and Kidwai Memorial Institute of Oncology, Bangalore, IN, ¹⁰Novartis Pharma AG, Basel, CH, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, US, ¹²Songklanagarind Hospital, Prince of Songkla University, Songkhla, TH
- 12:45 - 12:45 **168P - Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)**
- J. Subramanian¹, V. Moreno², J. Bosch-Barrera³, J. Pikiel⁴, R. Kristeleit⁵, W. Guo⁶, H. Danaee⁷, E. Im⁶, D. Roda⁸, ¹Saint Luke's Cancer Institute, Kansas City, US, ²START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, ES, ³ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta Hospital Universitari Josep Trueta), Girona, ES, ⁴Szpital Morski, Gdynia, PL, ⁵UCL Cancer Institute/Paul O'Gorman Building, London, GB, ⁶GlaxoSmithKline, Waltham, US, ⁷TESARO, Waltham, US, ⁸University Hospital, Valencia, ES
- 12:45 - 12:45 **169P - Patient-reported Outcomes (PROs) From Patients with ROS1-positive (ROS1+) Non-small Cell Lung Cancer (NSCLC) Receiving Entrectinib in the Global Phase 2 STARTRK-2 Study**
- J. Wolf¹, M.-J. Ahn², R. Doebele³, L. Paz-Ares⁴, F. Barlesi⁵, C. Rolfo⁶, S. Siena⁷, T. Seto⁸, A. Kapre⁹, E. Piau-Louis⁹, X. Huang⁹, B. Simmons⁹, A. Drilon¹⁰, ¹Uniklinik Köln, Cologne, DE, ²Samsung Medical Center (SMC)-Sungkyunkwan University School of



Medicine, Seoul, KR, ³University of Colorado, Aurora, US, ⁴University Hospital 12 De Octubre, Madrid, ES, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶University of Maryland School of Medicine, Baltimore, US, ⁷Università deli Studi di Milano, Milan, IT, ⁸National Kyushu Cancer Center, Fukuoka, JP, ⁹Genentech, South San Francisco, US, ¹⁰Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

12:45 - 12:45 **170P - Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC): An Updated Integrated Analysis**

M. Krebs¹, F. De Braud², S. Siena², A. Drilon³, R. Doebele⁴, M. Patel⁵, B.C. Cho⁶, S. Liu⁷, M.-J. Ahn⁸, C.-H. Chiu⁹, A.F. Farago¹⁰, C.-C. Lin¹¹, C. Karapetis¹², Y.-C. Li¹³, F. Barlesi¹⁴, B. Simmons¹⁵, X. Huang¹⁵, B. Pitcher¹⁶, R. Dziadziuszko¹⁷, ¹The Christie NHS Foundation Trust, Manchester, GB, ²Università deli Studi di Milano, Milan, IT, ³Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ⁴University of Colorado, Aurora, US, ⁵University of Minnesota, Minneapolis, US, ⁶Yonsei Cancer Center Yonsei University, Seoul, KR, ⁷Lombardi Cancer Center Georgetown University, Washington, US, ⁸Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ⁹Taipei Veterans General Hospital, Taipei, TW, ¹⁰Massachusetts General Hospital Cancer Center, Boston, US, ¹¹National Taiwan University Hospital, Taipei, TW, ¹²Flinders Medical Centre and Flinders University, Adelaide, AU, ¹³Hong Kong United Oncology Centre, Jordan, HK, ¹⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁵Genentech, South San Francisco, US, ¹⁶Hoffmann-La Roche Limited, Mississauga, CA, ¹⁷Medical University of Gdansk, Gdansk, PL

12:45 - 12:45 **171P - Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC**

G. Gao¹, Y. Wang², S. Ren¹, J. Zhao³, G. Chen⁴, J. Chen⁵, K. Gu⁶, R. Guo⁷, Y. Pan⁸, Q. Wang⁹, C. Zhou¹⁰, ¹Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, ²The First Affiliated Hospital Zhejiang University, Hangzhou, CN, ³Peking University Cancer Hospital and Institute, Beijing, CN, ⁴Harbin Medical University Cancer Hospital, Harbin, CN, ⁵Department of Thoracic Medicine, Hunan Cancer Hospital, changsha, CN, ⁶The First Affiliated Hospital of Anhui Medical University, Hefei, CN, ⁷Jiangsu Province Hospital, Nanjing, CN, ⁸The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, CN, ⁹Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, CN, ¹⁰Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN

12:45 - 12:45 **172P - Osimertinib vs comparator epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) as first-line treatment for EGFR mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA China study overall survival (OS)**

Y. Cheng¹, Y. He², W. Li³, H.-L. Zhang⁴, Q. Zhou⁵, B. Wang⁶, C. Liu⁷, A. Walding⁸, M. Saggese⁸, X. Huang⁸, Y. Liu⁹, R. Su⁹, S. Ramalingam¹⁰, ¹Jilin Provincial Cancer Hospital, Changchun, CN, ²Daping Hospital, Chongqing, CN, ³The First Hospital of Jilin University, Changchun, CN, ⁴Tangdu Hospital of Forth Military Medical University, Xi'An, CN, ⁵Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ⁶Subei People's Hospital, Yangzhou, CN, ⁷Xinjiang Medical University, Urumqi, CN, ⁸AstraZeneca, Cambridge, GB, ⁹AstraZeneca, Shanghai, CN, ¹⁰Winship Cancer Institute, Atlanta, US



- 12:45 - 12:45 **173P - Docetaxel/nintedanib as efficient treatment option after failure of immune oncology (IO) therapy: Real world evidence**
D.C. Christoph¹, F. Rizzo², K.-O. Kambartel³, S. Winke³, J. Panse⁴, D. Abdulla⁵, M. Scheffler⁵, I. Azeh⁶, M. Hoiczky⁷, A. Turki⁸, M. Metzenmacher¹, ¹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ²Evang. Kliniken Essen-Mitte, Essen, DE, ³Bethanien Hospital Moers-Lungenzentrum, Moers, DE, ⁴University Hospital Aachen, Aachen, DE, ⁵Uniklinik Köln, Cologne, DE, ⁶Gemeinschaftspraxis Dr. C. Schardt und I. Azeh, Gelsenkirchen, DE, ⁷Marien-Hospital Wesel, Wesel, DE, ⁸University Hospital Essen, Essen, DE
- 12:45 - 12:45 **174P - Efficacy and safety of treatments in ALK-positive non-small cell lung cancer: a Bayesian network meta-analysis of randomized controlled trials**
Y. Zhao, H. Liang, J. Li, S. Xiong, B. Cheng, C.C. Li, J. He, W. Liang, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN
- 12:45 - 12:45 **175P - Real-world treatment patterns and outcomes in patients (pts) with advanced, ALK+ non-small cell lung cancer (NSCLC) in Europe**
N. Stoyanov¹, D. Anderson², A. Combest³, B. Nguyen⁴, R. Ognar⁵, D. Reitsma⁴, P. Capart⁵, ¹PPD Bulgaria EOOD, Sofia, BG, ²PPD, LLC, Morristown, US, ³PPD, LLC, Wilmington, US, ⁴PPD, LLC, Bethesda, US, ⁵Medimix International, Boston, US
- 12:45 - 12:45 **176P - Osimertinib in Leptomeningeal metastases: Light at the end of a dark tunnel**
U. Batra, M. Sharma, A. Jain, P. Jain, Rajiv Gandhi Cancer Institute & Research Center, New Delhi, IN
- 12:45 - 12:45 **(Withdrawn)**
- 12:45 - 12:45 **178P - Quality of Life over time in incurable lung cancer and impact of molecular alterations: results of the Arbeitsgemeinschaft Palliativmedizin (APM) trial**
J. Kuon¹, M. Blasi², U. Laura¹, J. Vogt³, A. Mehnert⁴, B. Alt-Epping⁵, B. Van Oorschot⁶, F. Lordick⁷, J. Siermanns⁸, M. Ahlborn⁹, U. Ritterbusch¹⁰, S. Stevens¹¹, C. Kahl¹², A. Ruellan¹³, K. Matthias¹⁴, T. Kubin¹⁵, K. Stahlhut¹⁶, A. Heider¹⁷, M. Thomas¹, ¹Thoraxklinik Heidelberg, Heidelberg, DE, ²Ospedale San Paolo, Milan, IT, ³University Cancer Center Leipzig, Leipzig, DE, ⁴University Hospital Leipzig, Leipzig, DE, ⁵Universitätsmedizin Göttingen, Goettingen, DE, ⁶University Hospital Würzburg, Würzburg, DE, ⁷Universitätsklinikum Leipzig, Leipzig, DE, ⁸Kliniken Maria Hilf Mönchengladbach, Mönchengladbach, DE, ⁹Städtisches Klinikum Braunschweig, Braunschweig, DE, ¹⁰Westdeutsches Tumorzentrum, Essen, DE, ¹¹Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, ¹²Klinikum Magdeburg, Magdeburg, DE, ¹³Städtisches Klinikum Karlsruhe(Municipal Hosp), Karlsruhe, DE, ¹⁴Medizinische Hochschule Hannover, Hannover, DE, ¹⁵Klinikum Traunstein, Traunstein, DE, ¹⁶Immanuel Klinik und Poliklinik Rüdersdorf, Rüdersdorf, DE, ¹⁷Helios Klinikum Aue, Aue, DE
- 12:45 - 12:45 **179P - EGFR tyrosine kinase inhibitor with or without Anti-angiogenic agent for**



EGFR-mutant advanced non-small-cell lung cancer: A systematic review and meta-analysis

Z. Deng¹, Y. Qin², Y. Zhang¹, ¹West China Medical Center of Sichuan University, Chengdu, CN, ²West China Hospital of Sichuan University, Chengdu, CN

12:45 - 12:45

180P - A retrospective observational study of Osimertinib monotherapy treatment (t) in patients (p) with advanced (adv) Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M mutation-positive (mut+) treated within the Special Use Medication Program (SUMP) in Spain. OSIREX-Spanish Lung Cancer Group

V. Calvo De Juan¹, J. Terrasa Pons², P. Garrido Lopez³, M.R. Garcia Campelo⁴, F.D.A. Aparisi Aparisi⁵, D. Aguiar Bujanda⁶, C. Giron⁷, J. Hidalgo Coloma⁸, C. Aguado⁹, J.J. Garcia Gonzalez¹⁰, E. Esteban Gonzalez¹¹, M.T. Moran Bueno¹², O.J. Juan Vidal¹³, L.E. Chara Velarde¹⁴, J.L. Marti Ciriquian¹⁵, J.L. Gomez Aldarabi¹⁶, R. Lopez Castro¹⁷, M. Provencio Pulla¹⁸, ¹Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, ES, ²Hospital Universitario Son Espases, Palma de Mallorca, ES, ³Hospital Universitario Ramon y Cajal, Madrid, ES, ⁴Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ⁵FIHGUV - Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, ⁶Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES, ⁷Complejo Hospitalario de Burgos -Hospital General Yagüe, Burgos, ES, ⁸Hospital Universitario Arnau de Vilanova, Lleida, ES, ⁹Hospital Clinico Universitario San Carlos, Madrid, ES, ¹⁰CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, ¹¹Hospital Universitario Central de Asturias, Oviedo, ES, ¹²Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, ¹³Hospital Universitari i Politècnic La Fe, Valencia, ES, ¹⁴Hospital Universitario de Guadalajara, Guadalajara, ES, ¹⁵Hospital General Universitario de Alicante, Alicante, ES, ¹⁶Complejo Hospitalario Universitario de Albacete, Albacete, ES, ¹⁷University Clinical Hospital of Valladolid, Valladolid, ES, ¹⁸Hospital Puerta de Hierro-Majadahonda, Madrid, ES

12:45 - 12:45

181P - Real World Molecular Testing in Patients with EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC in routine practice in Germany - Interim results of the clinical registry PANORAMA

F. Griesinger¹, R. Büttner², K.-M. Deppermann³, N. Reinmuth⁴, W. Schütte⁵, M. Thomas⁶, M. Wroblewski⁷, C. Schumann⁸, ¹Pius Hospital, Oldenburg, DE, ²Uniklinik Köln, Köln, DE, ³Krankenhaus Gerresheim, Düsseldorf, DE, ⁴Asklepios Lung Clinic, Munich-Gauting, DE, ⁵Hospital Martha-Maria Halle-Doelau, Halle, DE, ⁶Thoraxklinik Heidelberg, Heidelberg, DE, ⁷AstraZeneca Germany, Wedel, DE, ⁸Klinikum Kempten-Oberallgaeu gGmbH, Kempten, DE

12:45 - 12:45

182P - Outcomes of Treated Patients with EGFR-mutated Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Exon 19 Deletions or L858R Substitution (Exon 21) Mutations: A Systematic Literature Review

K. Winfree¹, X. Wang², U. Kiiskinen¹, G. Reppen¹, C. Papagiannopoulos², M. Nassim², K. Haeussler², D. So², K. Taipale¹, C. Molife¹, M.-H. Jen¹, S. Traore¹, R. Varea¹, ¹Eli Lilly and Company, INDIANAPOLIS, US, ²ICON plc, Dublin, IE

12:45 - 12:45

183P - Alectinib in patients with ALK-positive advanced non-small cell lung cancer as first-line or sequential treatment in China :a multicentric real-world



study

X. Yang¹, X. Dong², Y. Liu³, B. Jin⁴, J. Zhao¹, J. Wang⁵, Y. Wang⁶, Y. Zhang⁷, M. Zhuo¹,
¹Peking University Cancer Hospital and Institute, Beijing, CN, ²Union Hospital Tongji Medical Collage of Huazhong University of Science and Technology, Wuhan, CN,
³Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN, ⁴The First Hospital, China Medical University, Shenyang, CN, ⁵PLA General Hospital, Beijing, CN, ⁶The Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, ⁷The No.1 hospital of Shijiazhuang, Shijiazhuang, CN

12:45 - 12:45 **184P - Real-world treatment patterns of patients with locally advanced/metastatic EGFRm NSCLC in Belgium**

K. Cuppens¹, L. Lodewyckx², I. Demedts³, L. Decoster⁴, B. Colinet⁵, K. Deschepper⁶, A. Janssens⁷, D. Galdermans⁸, T. Pieters⁹, ¹Virga Jesse Ziekenhuis, Hasselt, BE, ²AstraZeneca BELUX, Brussels, BE, ³AZ Delta campus Wilgenstraat, Roeselare, BE, ⁴UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, ⁵Grand Hopital de Charleroi Site Notre Dame, Charleroi, BE, ⁶AZ Nikolaas Hospital, St Niklaas, BE, ⁷University Hospital Antwerp (UZA), Edegem, BE, ⁸Ziekenhuisnetwerk Antwerpen-Middelheim, Antwerp, BE, ⁹Cliniques Universitaires St. Luc, Brussels, BE

12:45 - 12:45 **185P - Treatment patterns of EGFR mt+ NSCLC IV pts: Real world data of the NOWEL network**

J. Roeper¹, M. Falk², S. Schatz², M. Tiemann², C. Wesseler³, G. Wiest³, S. Sackmann⁴, D. Ukena⁴, F. Griesinger⁵, ¹Pius Hospital Oldenburg, University of Oldenburg, Berlin, DE, ²Hematopathology Hamburg, Hamburg, DE, ³Asklepios Klinik Harburg, Hamburg, DE, ⁴Klinikum Bremen Ost, Bremen, DE, ⁵Pius Hospital, University of Oldenburg, Oldenburg, DE

12:45 - 12:45 **187P - Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC)**

S. Popat¹, O.T. Brustugun², J. Cadranel³, E. Felip⁴, M. Garassino⁵, F. Griesinger⁶, A. Helland⁷, M. Hochmair⁸, M. Pérol⁹, N. Bent-Ennakhil¹⁰, C. Kruhl¹⁰, S. Novello¹¹, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Drammen Hospital, Drammen, NO, ³AP-HP Hôpital Tenon and GRC#4 Therascan Sorbonne Université Paris, Paris, FR, ⁴Vall d'Hebron University Hospital, Barcelona, ES, ⁵Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁶Pius Hospital, University of Oldenburg, Oldenburg, DE, ⁷Oslo University Hospital, Oslo, NO, ⁸Otto Wagner Spital, Vienna, AT, ⁹Centre Léon Bérard, Lyon, FR, ¹⁰Takeda Pharmaceuticals International, Zurich, CH, ¹¹Università Degli Studi Di Torino - Orbassano, Orbassano, IT

12:45 - 12:45 **188P - Treatment Duration and Adherence in ALK+ Non-Small Cell Lung Cancer Patients Treated with Brigatinib Following Prior ALK TKI Therapy in the US**

H. Lin¹, Y. Wu², M. Gorritz³, C. McGuiness³, W.-T. Huang³, C.-C. Chen³, M. Jahanzeb⁴, ¹Millennium Pharmaceutical (subsidiary of Takeda Pharmaceutical Company Ltd), Cambridge, US, ²Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, US, ³IQVIA, Inc., Plymouth Meeting, US, ⁴Florida Precision Oncology, Boca Raton, US

12:45 - 12:45 **190P - Patterns of Extra-Cranial Disease Progression in Oncogene-Addicted**



Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitors (TKI) - A Single Centre Analysis

N. Tokaca¹, E. Grainger², L. Finneran², L. Kilburn³, N. Yousaf⁴, S. Popat⁴, F. McDonald⁴,
¹The Francis Crick Institute, London, GB, ²Institute of Cancer Research, PT, GB,
³Institute of Cancer Research, Sutton, GB, ⁴Royal Marsden Hospital NHS Foundation Trust, London, GB

12:45 - 12:45 **191P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small-cell lung cancer patients progressing on crizotinib : A multicenter study**

W. Wang¹, C. Xu², Q. Zhang³, W. Zhuang³, Z. Song¹, Y. Zhu⁴, G. Chen³, M. Fang¹, T. Lv⁵, Y. Song⁵,
¹Zhejiang Cancer Hospital, Hangzhou, CN, ²Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, ³Fujian Cancer Hospital, Fuzhou, CN, ⁴Zhejiang Rongjun Hospital, Jiaxing, CN, ⁵Jinling Hospital, Nanjing, CN

12:45 - 12:45 **192P - Incidence of T790M on Progression based on First Line EGFR TKI therapy in the Midlands, UK**

R. Powell¹, R. Kussaibati¹, S. Baijal², ¹Heartlands Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB, ²Heartlands Hospital-Heart of England NHS Foundation Trust, Birmingham, GB

12:45 - 12:45 **193P - Efficacy of nintedanib plus docetaxel in patients with advanced refractory Epidermal Growth Factor Receptor (EGFR) mutant non-small cell lung cancer patients.**

M. Riudavets¹, J. Bosch-Barrera², L. Cabezón Gutiérrez³, P. Diz Taín⁴, A. Hernández González⁵, S. Ponce Aix⁶, D.M. Roa Garcia², J.M. Sanchez Torres⁷, M. Alonso García⁸, M.A. Insa Molla⁹, E. Gálvez Muñoz¹⁰, X. Mielgo Rubio¹¹, M.T. Moran Bueno¹², M. Majem Tarruella¹,
¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ²ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta Hospital Universitari Josep Trueta), Girona, ES, ³Hospital Universitario de Torrejón, Torrejón, ES, ⁴Complejo Asistencial Universitario de León, León, ES, ⁵Hospital de Mataró, Mataró, ES, ⁶University Hospital 12 De Octubre, Madrid, ES, ⁷Hospital Universitario de La Princesa, Madrid, ES, ⁸Hospital Universitario Virgen del Rocío, Sevilla, ES, ⁹Hospital Clínico Universitario de Valencia, Valencia, ES, ¹⁰Hospital General de Elda, Valencia, ES, ¹¹Hospital Universitario Fundación Alcorcón, Alcorcon, ES, ¹²Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES

12:45 - 12:45 **194P - Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first or second generation tyrosine kinase inhibitor (1-2 gen TKI)**

A. Dal Maso¹, A. Ferro², M. Lorenzi², V. Polo³, D. Scattolin⁴, A. Del Conte⁵, E. Scoccia⁴, S. Frega⁶, L. Bonanno⁶, S. Indraccolo², F. Calabrese⁷, V. Guarneri⁶, P.F. Conte⁶, G. Pasello⁶,
¹IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ²Istituto Oncologico Veneto - IRCCS, Padova, IT, ³Ospedale Ca' Foncello, AULSS 2 Marca Trevigiana, Treviso, IT, ⁴Università degli Studi di Padova, Padova, IT, ⁵Centro di Riferimento Oncologico - IRCCS, Aviano, IT, ⁶Istituto Oncologico Veneto IRCCS, Padova, IT, ⁷Pathology Unit, Padova, IT

12:45 - 12:45 **195P - Cost-effectiveness of lorlatinib in second-line or later therapy of ALK positive Non-small Cell Lung Cancer (NSCLC) in Spain.**



A. Calles Blanco¹, D. Vicente², P. Rebollo³, M. Cerezales³, L.F. García⁴, J. Soto⁵, ¹Hospital General Universitario Gregorio Marañón, Madrid, ES, ²Hospital Universitario Virgen Macarena, Sevilla, ES, ³Ingress-health Spain, Oviedo, ES, ⁴Pfizer, Madrid, ES, ⁵Pfizer SLU, Madrid, ES

12:45 - 12:45 **196P - Value of rebiopsy in advanced Epidermal Growth Factor Receptor (EGFR) mutated Non Small Cell Lung Cancer: real-world data.**

R. Conde¹, S. Ferreira¹, E. Campoa², T. Almodovar¹, ¹Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT, ²Hospital Distrital de Faro, Faro, PT

12:45 - 12:45 **197P - Real-world T790M mutation frequency and impact of re-biopsy in advanced Non-Small-Cell Lung Cancer**

I.S. Pereira¹, C. Gaspar², M. Pina², A. Rodrigues², J. Oliveira², C. Oliveira², I. Pousa², A. Rosinha², M. Cassiano², S. Alves², M. Soares³, I. Azevedo², ¹Instituto Portugues de Oncologia Centro do Porto E.P.E. (IPO-Porto), Porto, PT, ²Instituto Português de Oncologia do Porto E.P.E. (IPO-Porto), Porto, PT, ³Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), Porto, PT

12:45 - 12:45 **198P - Analysis of efficacy, safety and survival of first generation EGFR-TKI plus Apatinib in treating advanced lung adenocarcinoma after EGFR-TKI treatment failure**

Y. Feng¹, H. Zhu¹, X. Hu¹, Y. Liu¹, P. Xing¹, H. Wang¹, X. Ji², Z. Dai², Y. Shi¹, ¹Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN, ²Huanxing Cancer Hospital of Chaoyang District, Beijing, CN

12:45 - 12:45 **199P - Comparison of Detection of Epidermal Growth Factor Receptor (EGFR) Gene Mutation in Peripheral Blood Plasma (Liquid Biopsy) with Cytological Specimens in Lung Adenocarcinoma Patients**

L. Wulandari, G. Soegiarto, A. Febriani, F. Fatmawati, S. Sahrin, Dr. Soetomo Hospital-Airlangga University Medical School, Surabaya, ID

12:45 - 12:45 **200P - Anlotinib combination with docetaxol for patients with advanced refractory non-small-cell lung cancer: a phase 2, single-arm trial**

X. Chen¹, J. Shen², X. Li³, S. Yang³, K. Wu⁴, B. Xia³, B. Wang³, J. Wang⁵, S. Zheng³, S. Ma¹, ¹Hangzhou First People's Hospital, Hangzhou, CN, ²The fourth clinical college of Zhejiang chinese medical university, Hangzhou, CN, ³Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou Cancer Hospital, Hangzhou, CN, ⁴Hangzhou Cancer Hospital, Hangzhou, CN, ⁵Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, CN

12:45 - 12:45 **201P - Clinical Outcomes in advanced NSCLC patients with EGFR exon 20 insertion mutation.**

C. Morita¹, T. Yoshida¹, M. Shirasawa¹, K. Masuda¹, Y. Matsumoto¹, Y. Shinno¹, S. Yagishita¹, Y. Okuma¹, Y. Goto², H. Horinouchi³, N. Yamamoto¹, N. Motoi¹, Y. Ohe³, ¹National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP, ²National Cancer Center Hospital, Department of Thoracic Oncology, Tokyo, JP, ³National Cancer Center Hospital, Tokyo, JP



- 12:45 - 12:45 **202P - A predictive test for competing targeted therapy (TT) choice in patients with advanced non-small cell lung cancer (NSCLC).**
O. Obodnikov, PII Shupika National Medical Academy of Postgraduate Education, Kiev, UA
- 12:45 - 12:45 **203P - Clinical Impact of New Generation Sequencing (NGS) in Treatment Decisions in Advanced NSCLC**
M.I. Aparicio Salcedo, M. García Pardo De Santayana, M. Alva Bianchi, I. Martínez Delfrade, M. Arregui Valles, V.C. Tirado Anula, P. Elvira Ruiz, D. Sánchez García, F. Alijo, M. Galera, R.M. Álvarez, A. Calles Blanco, Hospital General Universitario Gregorio Marañón, Madrid, ES
- 12:45 - 12:45 **204P - Outcomes with liquid biopsy alone to determine the Epidermal Growth Factor Receptor mutation status in poor performance, biopsy ineligible advanced Non-Small Cell Lung Cancer**
A. Pandey¹, A. Singh², S. Dutt³, ¹Tata Memorial Hospital, Mumbai, IN, ²Indira Gandhi Institute of Medical Sciences, Patna, IN, ³Oncquest Laboratories, Mumbai, IN
- 12:45 - 12:45 **205P - Preferred and achieved goals of patients with metastatic lung cancer and their oncologists in end-of-life therapy**
A. Mieras¹, R. Pasmán², B. Onwuteaka-Philipsen², A. Becker³, ¹Academic Medical Center, University of Amsterdam, Amsterdam, NL, ²Amsterdam UMC, Amsterdam, NL, ³Vrije University Medical Centre (VUMC), Amsterdam, NL
- 12:45 - 12:45 **206P - Clinical Utility of ctDNA Next Generation Sequencing (NGS) for Target Identification in Diagnostic and Acquired Resistance Settings in Metastatic NSCLC - A Single Centre Experience**
N. Tokaca¹, K. Sreter², I. Faull³, L. Richard³, N. Yousaf², S. Popat², ¹The Francis Crick Institute, London, GB, ²Royal Marsden Hospital NHS Foundation Trust, London, GB, ³Guardant Health, Inc., Redwood City, US
- 12:45 - 12:45 **207P - Real world treatment patterns for metastatic NSCLC at IRST, Italy**
S. Manunta¹, I. Massa², N. Gentili², W. Balzi², F. Foca¹, M. Altini², V. Danesi², M. Burgio¹, G. Bronte¹, A. Verlicchi¹, F. Ejzykowicz³, A. Delmonte¹, ¹IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS S.r.l., Meldola, IT, ²Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, ³Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, US
- 12:45 - 12:45 **208P - Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer.**
M. Buess¹, T. Wallrabenstein¹, J. Del Rio², A. Templeton¹, ¹St. Claraspital AG, Basel, CH, ²Basel University, Basel, CH
- 12:45 - 12:45 **209P - Real-World Treatment Patterns and Outcomes for Patients with Advanced Non-Small Cell Lung Cancer in Greece**
K. Syrigos¹, E. Kokkotou², A. Papaspiliou³, L. Stournara⁴, V. Grammatikou⁵, F.



Ejzykowicz⁶, A. Charpidou⁷, ¹Medical School, National & Kapodistrian University of Athens, Athens, GR, ²National and Kapodistrian University of Athens, Athens, GR, ³Oncology Unit, Third Department of Medicine, Athens Medical School, Sotiria, General Hospital of Athens, Athens, Greece, Athens, GR, ⁴National and Kapodistrian University of Athens School of Medicine, Athens, GR, ⁵MSD Greece, Athens, GR, ⁶Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, US, ⁷University of Athens, Sotiria General Chest Diseases Hospital, Athens, GR

- 12:45 - 12:45 **210P - Real-world (RW) clinical outcomes of patients with metastatic non-small cell lung cancer (mNSCLC) in the United Kingdom**
J. Lester¹, C. Escriu², S. Khan³, E. Hudson⁴, T. Mansy⁵, A. Conn⁶, S. Chan⁷, C. Powell¹, J. Brock⁸, J. Conibear⁹, L. Nelles¹⁰, V. Nayar¹⁰, X. Zhuo¹¹, A. Durand¹¹, A. Amin¹¹, P. Martin¹¹, X. Zhang¹², V. Pawar¹³, ¹South West Wales Cancer Institute Singleton Hospital, Sketty, Swansea, GB, ²The Clatterbridge Cancer Centre, Wirral, GB, ³Nottingham University Hospitals NHS Trust, Nottingham, GB, ⁴Velindre Cancer Centre, Cardiff, GB, ⁵South Tees Hospitals NHS Foundation Trust, Middlesbrough, GB, ⁶Bradford Teaching Hospitals NHS Foundation Trust, Bradford, GB, ⁷York Teaching Hospital NHS Foundation Trust, York, GB, ⁸Brighton and Sussex University Hospitals NHS Trust, Brighton, GB, ⁹Barts Health NHS Trust, London, GB, ¹⁰SVMPharma, Fleet, GB, ¹¹Merck KgaA, Darmstadt, DE, ¹²EMD Serono, Billerica, US, ¹³EMD Serono, Rockland, US
- 12:45 - 12:45 **211P - Impact of geriatric evaluation in bronchial cancer management in elderly patients about 110 cases**
B. Wassila, CHU Tlemcen, Tlemcen, DZ
- 12:45 - 12:45 **212P - Hospital based observational study on the tolerability, and efficacy of adding High dose Vit D in combination with chemotherapy with stage IV lung cancer patients - who are mutation negative**
S. Attili¹, O. Reddy², M. Singaraju³, ¹Omega Hospitals, Hyderabad, IN, ²Kidwai Institute of Oncology, Bangalore, IN, ³Omega Hospitals, HYDERABAD, IN
- 12:45 - 12:45 **213P - Blood T cell diversity associated with the prognosis of advanced non-small-cell lung carcinoma treated with first-line pemetrexed based chemotherapy**
Q. Li¹, Z. Zhang¹, Y. Xu², Z. Liu², L. Liang¹, ¹Peking University Third Hospital, Beijing, CN, ²Geneplus Beijing, Beijing, CN
- 12:45 - 12:45 **214P - Recent Advances in Endobronchial Cancer Treatment: Intratumoral Injection of Cisplatin**
F. Celikoglu, Bayindir Saglik Grubu - Ozel Bayindir Hospital, Ankara, TR
- 12:45 - 12:45 **215P - Surgery for Stage IV Non-Small Cell Lung Cancer: Lobectomy or Sublobar Resection?**
H. Liang¹, Y. Zhang², W. Liang¹, J. He¹, ¹The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ²The first affiliated hospital of Guangzhou Medical University, Guangzhou, CN
- 12:45 - 12:45 **216P - Association between patient-reported toxicity and health-related quality**



of life in (locally-) advanced non-small cell lung cancer

L. Van Der Weijst, V. Surmont, W. Schrauwen, Y. Lievens, UZ Gent - Universitair Ziekenhuis Gent, Gent, BE

- 12:45 - 12:45 **217P - Predictive Test for individualized chemotherapy (CT) choice in patients with advanced non-small cell lung cancer (NSCLC).**
O. Obodnikov, PII Shupika National Medical Academy of Postgraduate Education, Kiev, UA
- 12:45 - 12:45 **218P - Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis of randomized controlled trials.**
L. Cantini¹, F. Merloni², S. Rinaldi¹, E. Lenci², G. Marcantognini², T. Meletani², I. Fiordoliva², F. Morgese², M. Torniai², G. Ricci², R. Giampieri¹, R. Berardi², ¹AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, IT, ²AOU Ospedali Riuniti Ancona, Torrette di Ancona, IT
- 12:45 - 12:45 **219TiP - SGNLVA-005: Open-Label, Phase 2 Study of Ladiratuzumab Vedotin (LV) for Advanced Lung Malignancies**
I. Anderson¹, A. Lee², R. Sanborn³, J. Bruce⁴, R. Graham⁵, T. Guthrie⁶, Y. Wang⁷, Z. Wang⁷, N. Gabrail⁸, ¹St. Joseph Health Cancer Center, Santa Rosa, US, ²UT Health East Texas HOPE Cancer Center, Tyler, US, ³Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, US, ⁴Carbone Cancer Center, University of Wisconsin, Madison, US, ⁵Erlanger Oncology and Hematology, Chattanooga, US, ⁶21st Century Oncology, Jacksonville, US, ⁷Seattle Genetics, Inc., Bothell, US, ⁸Gabrail Cancer Center, Canton, US
- 12:45 - 12:45 **220TiP - SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer (NSCLC). A randomised phase III trial.**
F. Mcdonald¹, K.M. Mak², J. Teague³, D. Landau⁴, G. Hanna⁵, J. Conibear⁶, L. Farrelly³, N. Counsell³, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²UCL - University College London, London, GB, ³University College London, WT TJ, GB, ⁴Guy's and St Thomas' Hospital, London, GB, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶Barts Health NHS Trust, London, GB
- 12:45 - 12:45 **221TiP - AcceleRET Lung: A Phase 3 Study of Pralsetinib for First-Line Treatment of RET Fusion+ Metastatic Non-Small Cell Lung Cancer (NSCLC)**
B. Besse¹, E. Felip², C. Clifford³, M. Louie-Gao³, J. Green³, C. Turner³, S. Popat⁴, ¹Institut Gustave Roussy, Villejuif, FR, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Blueprint Medicines, Cambridge, US, ⁴The Royal Marsden Hospital, London, GB
- 12:45 - 12:45 **222TiP - A Phase II trial of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) harboring MET alterations: VISION study**
J. Mazieres¹, E. Felip², R. Veillon³, A. Cortot⁴, M. Garassino⁵, S. Viteri⁶, H. Senellart⁷, J. Van Meerbeeck⁸, N. Reinmuth⁹, P. Conte¹⁰, D. Kowalski¹¹, J. Scheele¹², J. Straub¹³, R. Bruns¹⁴, P. Paik¹⁵, ¹CHU Toulouse - Hôpital Larrey, Toulouse, FR, ²Vall d'Hebron University Hospital, Barcelona, ES, ³service des maladies du Sang - CHU du Ht Leveque,



FR, ⁴Hospital Albert Calmette, Lille, FR, ⁵Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁶Instituto Universitario Dexeus, Barcelona, ES, ⁷ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁸University Hospital Antwerp (UZA), Edegem, BE, ⁹Asklepios Lung Clinic, Munich-Gauting, DE, ¹⁰Istituto Oncologico Veneto IRCCS, Padova, IT, ¹¹Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, ¹²Merck KGaA, Darmstadt, DE, ¹³Merck KGaA - Germany, Darmstadt, DE, ¹⁴Department of Biostatistics, Merck KGaA, Darmstadt, DE, ¹⁵Memorial Sloan-Kettering Cancer Center, New York City, US

- 12:45 - 12:45 **223TiP - Targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours (CRUK/16/020)**
F. Mcdonald¹, M. Guckenberger², S. Popat¹, C. Faivre-Finn³, N. Andratschke², A. Riddell¹, G. Hanna⁴, K. Franks⁵, S. Harrow⁶, R. Patel⁷, P. Diez⁷, L. Kilburn⁸, C. Toms⁹, J. Bliss⁸, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Universitätsspital Zürich, Zürich, CH, ³The Christie NHS Foundation Trust, Manchester, GB, ⁴Peter MacCallum Cancer Centre, Melbourne, AU, ⁵St. James's University Hospital Leeds, Leeds, GB, ⁶Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁷Mount Vernon Cancer Centre, Northwood, GB, ⁸Institute of Cancer Research, Sutton, GB, ⁹Royal Marsden Hospital Institute of Cancer Research, Sutton, GB
- 12:45 - 12:45 **Metastases to and from the lung**
- 12:45 - 12:45 **227P - Hypofractionated Image-Guided Radiotherapy (h-IGRT) for lung cancer adrenal metastasis: administered dose is crucial**
F. Arcidiacono¹, C. Aristei², P. Anselmo¹, A. Marchionni², M. Italiani³, M. Lupattelli², F. Trippa¹, G. Ingrosso², E. Maranzano³, ¹Azienda Ospedaliera Sta Maria, Terni, IT, ²Azienda Ospedaliera Santa Maria della Misericordia, Perugia, IT, ³Azienda Ospedaliera Santa Maria, Terni, IT
- 12:45 - 12:45 **228P - A single-centre experience on surgical management of pericardial effusion in oncological patients**
A.A. Farmidi¹, G. Lopez², E. Katumalla², A. Beeman², P. Perikleous², J. Finch², V. Anikin², E. Beddow², N. Asadi², ¹Royal Brompton, London, GB, ²Royal Brompton Hospital, London, GB
- 12:45 - 12:45 **229P - The prognostic effect of lymph node dissection in secondary lung tumor metastasectomies**
S. Duman¹, M. Ülker², F. Amirov¹, B. Çimenoğlu¹, S. Erus³, B. Özkan¹, M. Kara¹, A. Toker¹, ¹Istanbul Faculty of Medicine, Istanbul, TR, ²Istanbul University - Faculty of Medicine, Istanbul, TR, ³Koç University Hospital, Istanbul, TR
- 12:45 - 12:45 **230P - Prognostic factors for survival in patients with metastatic lung adenocarcinoma. Analysis of the SEER database**
B. Campos Balea¹, J. De Castro Carpeño², B. Massutí³, D. Vicente Baz⁴, D. Pérez Parente⁴, P. Ruiz Gracia⁴, M. Cobo⁵, L. Crama⁴, ¹Hospital Universitario Lucus Augusti (HULA), Lugo, ES, ²Hospital Universitario La Paz, Madrid, ES, ³Hospital Universitario



Alicante / ISABIAL, Alicante, ES, ⁴Roche Farma S.A, Madrid, ES, ⁵Regional University Hospital of Málaga, IBIMA, Málaga, ES

- 12:45 - 12:45 **231P - Lung Cancer Stem Cells From Lymph Nodes Aspirates Express Immunomodulatory Molecules**
A. Raniszewska¹, I. Kwiecien², R. Sokolowski², E. Rutkowska², J. Domagala-Kulawik¹,
¹Medical University of Warsaw, Warsaw, PL, ²Military Medical Institute, Warsaw, PL
- 12:45 - 12:45 **232P - Immune Checkpoint Inhibitors: Another Way to Treat Non-small-cell Lung Cancer with Brain Metastases?**
S.-Y. Zheng¹, H.-J. Cui², ¹Beijing University of Chinese Medicine, Beijing, CN, ²China-Japan Friendship Hospital, Beijing, CN
- 12:45 - 12:45 **Mesothelioma**
- 12:45 - 12:45 **235P - Questioning the prognostic role of BAP-1 in malignant pleural mesothelioma: a cohort study and meta-analysis.**
F. Pecci¹, L. Cantini², A. Murrone³, M. Tomasetti¹, I. Fiordoliva⁴, C. Copparoni¹, F. Morgese⁴, S. Rinaldi², P. Mazzanti², F. Barbisan², C. Rubini², A. Cimadamore¹, M. Scarpelli¹, L. Santarelli¹, R. Berardi⁴, ¹Università Politecnica delle Marche, Ancona, IT, ²AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, IT, ³università politecnica delle Marche, Ancona, IT, ⁴AOU Ospedali Riuniti Ancona, Torrette di Ancona, IT
- 12:45 - 12:45 **236P - Profiling oncogenic dependency on pro-survival BCL-2 genes in malignant pleural mesothelioma**
D. Xu, R.-W. Peng, R. Schmid, Inselspital - University Hospital Bern - Universitätsklinik für Thoraxchirurgie, Bern, CH
- 12:45 - 12:45 **237P - Malignant pleural mesothelioma: single-center experience of multimodality treatment**
O. Mamontov¹, K. Senchik², M. Gelfond², A. Barchuk¹, E. Levchenko¹, ¹FSBI "Petrov Research Institute of Oncology" of the Ministry of Healthcare of the Russian Federation, Saint Petersburg, RU, ²FSBI "Petrov Research Institute of Oncology" of the Ministry of Healthcare of the Russian Federation, Saint-Petersburg, RU
- 12:45 - 12:45 **Miscellaneous**
- 12:45 - 12:45 **241P - Varied molecular features and clinical characteristics associated with autoimmune diseases in advanced thymic epithelial tumors**
J. Hellyer¹, S. Singhal¹, S. Padda¹, H. Wakelee², ¹Stanford Comprehensive Cancer Institute, Stanford, US, ²Stanford University, Stanford, US
- 12:45 - 12:45 **242P - The Effect Of Preoperative Fasting Period On Postoperative Healing In Thoracic Surgery: Prospective Randomized Controlled Study**



H. Aslanoglu¹, C. Atinkaya Baytemir², S. Ozturk³, ¹Health Science University, Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital, Istanbul, TR, ²Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital, Istanbul, TR, ³Maltepe University, Istanbul, TR

- 12:45 - 12:45 **243P - Cytology-histology concordance for diagnosis, histological subtyping and molecular profiling of lung cancer**
I. Gkiozos¹, C. Merkouri¹, D. Grapsa², G. Tournas¹, C. Fevranoglou¹, G. Stratakos¹, E. Politi¹, K. Syrigos¹, ¹Medical School, National & Kapodistrian University of Athens, Athens, GR, ²National and Kapodistrian University of Athens, Athens, GR
- 12:45 - 12:45 **244P - Surgical Management of Intra-Thoracic Sarcomas and other massive tumour tamponade**
J. Farag, University of Sydney, Sydney, AU
- 12:45 - 12:45 **245P - Integrating patients' quality of life (QoL) into clinical practice: a Delphi method-based consensus among French physicians managing lung cancer patients**
V. Westeel¹, M. Bourdon², A. Cortot³, D. Debieuvre⁴, A.C. Toffart⁵, M. Acquadro⁶, B. Arnould⁶, J. Lambert⁶, F.-E. Cotte⁷, A.-F. Gaudin⁷, H. Lemasson⁸, ¹Centre Hospitalier Universitaire de Besançon, Besancon, FR, ²Institut de Cancérologie de l'Ouest, Nantes, FR, ³Hospital Albert Calmette, Lille, FR, ⁴Hopital Emile Muller, Mulhouse, FR, ⁵CHU de Grenoble-Alpes- Le site nord à La Tronche - Hopital Michallon, La Tronche, FR, ⁶ICON plc, Lyon, FR, ⁷Bristol Myers Squibb, Rueil-Malmaison, FR, ⁸Bristol-Myers Squibb, Rueil-Malmaison, FR
- 12:45 - 12:45 **246P - Single-Centre Nutritional Management Review of Thoracic Oncology Patients within a Newly Established Dietetic Service**
D. Aresti¹, K. Sreter², S. Popat³, ¹Kingston Hospital, Kingston upon Thames, GB, ²KBC Sisters of Mercy-Sestre Milosrdnice University Hospital Center, Zagreb, HR, ³The Royal Marsden Hospital, London, GB
- 12:45 - 12:45 **247P - Breathing in a New Era: a comparative analysis of lung cancer policies across Europe**
M. Bussell, The Economist Intelligence Unit, London, GB
- 12:45 - 12:45 **248P - MyChristie-MyHealth: Introducing electronic Patient Reported Outcome Measures (ePROMs) in routine practice to revolutionise cancer care**
M. Christodoulou¹, N. Khalil¹, P. Rust¹, D. Thomson¹, E. Smith¹, S. Howell¹, J. Price¹, J. Fenemore¹, H. Neal¹, E. Halkyard¹, M. Barker-Hewitt¹, A. Payne², W. Dale¹, R. Bristow³, J. Yorke¹, C. Faivre-Finn¹, ¹The Christie NHS Foundation Trust, Manchester, GB, ²The University of Manchester, Manchester, GB, ³The University of Manchester and The Christie NHS Foundation Trust, Manchester, GB
- 12:45 - 12:45 **249TiP - SYMptom monitoring with Patient-Reported Outcomes using a web application among LUNG cancer patients in the Netherlands (SYMPRO-Lung)**
N. Billingsy¹, E. Veldhuijzen², V. Tromp³, J. Belderbos⁴, N. Aaronson⁵, H.-J. Bogaard³, B.



Onwuteaka-Philipsen³, L. Van De Poll-Franse⁴, J. Hugtenburg³, I. Walraven⁴, C. Van Den Hurk⁶, A. Becker⁷, ¹Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ²NCI, Amsterdam, NL, ³Amsterdam UMC, Amsterdam, NL, ⁴Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁵NKI-AVL, Amsterdam, NL, ⁶Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, NL, ⁷Vrije University Medical Centre (VUMC), Amsterdam, NL

12:45 - 12:45

250TiP - CANOPY program: Canakinumab (Cana) in patients (pts) with non-small cell lung cancer (NSCLC)

L. Paz-Ares¹, E. Garon², T. Mok³, A. Ardizzoni⁴, F. Barlesi⁵, B.C. Cho⁶, G. De Castro⁷, P. De Marchi⁸, E. Felip⁹, Y. Goto¹⁰, A. Greystoke¹¹, S. Lu¹², D.W.T. Lim¹³, M. Reck¹⁴, B. Solomon¹⁵, D. Spigel¹⁶, D.S.W. Tan¹⁷, M. Thomas¹⁸, J.C.H. Yang¹⁹, B. Johnson²⁰, ¹University Hospital 12 De Octubre, Madrid, ES, ²David Geffen School of Medicine at UCLA/TRIO-US Network, Los Angeles, US, ³Chinese University of Hong Kong, Shatin, HK, ⁴S. Orsola-Malpighi University Polyclinic, Bologna, IT, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶Yonsei Cancer Center Yonsei University, Seoul, KR, ⁷Instituto do Câncer do Estado de São Paulo, São Paulo, BR, ⁸Hospital de Câncer de Barretos, São Paulo, BR, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰National Cancer Center Hospital, Department of Thoracic Oncology, Tokyo, JP, ¹¹The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ¹²Shanghai Chest Hospital, Jiaotong University, Shanghai, CN, ¹³National Cancer Centre Singapore, Singapore, SG, ¹⁴LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, DE, ¹⁵Peter MacCallum Cancer Centre, Melbourne, AU, ¹⁶Sarah Cannon Research Institute, Nashville, US, ¹⁷NCCS - National Cancer Centre Singapore, Singapore, SG, ¹⁸Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, DE, ¹⁹Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, TW, ²⁰Dana-Farber Cancer Institute, Boston, US



13:30 - 14:30 Bristol-Myers Squibb - The future of immuno-oncology in NSCLC Room A
Moderation: M. Reck, Thoracic Oncology Dept., Krankenhaus Grosshansdorf, Grosshansdorf, DE

13:30 - 13:35 **Welcome and introductions**
M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

13:35 - 13:55 **Exploring the current and evolving 1L NSCLC landscape**
M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

13:55 - 14:10 **Long-term survival benefit and unanswered questions in 2L**
J. Brahmer, Johns Hopkins Hospital, Baltimore, US

14:10 - 14:25 **Emerging research with I-O in non-metastatic NSCLC**
V. Westeel, Centre Hospitalier Universitaire de Besançon, Besancon, FR

14:25 - 14:30 **Closing remarks and audience Q&A**
M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

14:40 - 16:20 ESMO-IASLC Best Abstracts Room B
Moderation: F. Barlesi¹, C. Faivre-Finn², ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Clinical Oncology Department, The Christie NHS Foundation Trust, Manchester, GB

14:40 - 14:52 **10 - Genetic evolution from preinvasive lesions to invasive NSCLC in TRACERx**
H. Zhai¹, C. Puttick², D. Moore³, M. Bakir², S. Ward², T. Watkins², A. Rowan², R. Veeriah³, N. Kanu³, N. Mcgranahan³, C. Swanton², M. Jamal-Hanjani³, ¹University College London, London, GB, ²Francis Crick Institute, London, GB, ³University College London Cancer Institute, London, GB

14:52 - 15:02 **Invited Discussant 10**
A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

15:02 - 15:14 **One LBA TBC**

15:14 - 15:26 **1250 - Final Efficacy Results From IMpower132: First-Line (1L) Atezolizumab (atezo) + Carboplatin/Cisplatin + Pemetrexed in Patients (pts) With Stage IV Non-Squamous (nsq) NSCLC**
M. Nishio¹, F. Barlesi², S. Ball³, R. Bordoni⁴, M. Cobo⁵, P. Dubray Longeras⁶, J. Goldschmidt, Jr⁷, S. Novello⁸, F. Orlandi⁹, R. Sanborn¹⁰, Z. Szalai¹¹, G. Ursol¹², D. Mendus¹³, L. Wang¹³, X. Wen¹³, M. Mcclelland¹³, T. Hoang¹³, S. Phan¹³, M. Socinski¹⁴, ¹Cancer Institute Hospital of JFCR, Tokyo, JP, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³Queen's Hospital, Romford, GB, ⁴Northside Hospital Cancer Institute, Marietta, US, ⁵Regional University Hospital of Málaga, IBIMA, Málaga, ES, ⁶Centre Jean



Perrin, Clermont-Ferrand, FR, ⁷Blue Ridge Cancer Care, Blacksburg, US, ⁸Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ⁹Instituto Nacional del Tórax, Santiago, CL, ¹⁰Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, US, ¹¹Petz Aladár County Teaching Hospital, Gyor, HU, ¹²Acinus, Kirovograd, UA, ¹³Genentech, Inc, South San Francisco, US, ¹⁴AdventHealth Cancer Institute, Orlando, US

15:26 - 15:41 **Invited Discussant One LBA TBC and 1250**

D. Planchard, Institut Gustave Roussy, Villejuif, FR

15:41 - 15:53 **1260 - Primary analysis of MET inhibitor (METi) capmatinib (CAP) plus 3rd generation EGFR TKI nazartinib (NAZ) in treatment (tx) naive or pretreated patients (pts) with EGFR-mutant NSCLC**

E. Felip¹, V. Minotti², R. Soo³, J. Wolf⁴, B. Solomon⁵, D. Tan⁶, A. Ardizzoni⁷, D.H. Lee⁸, L. Sequist⁹, F. Barlesi¹⁰, L. Paz-Ares¹¹, D. Rodriguez Abreu¹², M.R. Garcia Campelo¹³, M. Sprauten¹⁴, L. O'Sullivan Djentuh¹⁵, R. Belli¹⁶, S. Glaser¹⁵, M. Zou¹⁷, M. Giovannini¹⁸, J.C.-H. Yang¹⁹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Azienda Ospedaliera di Perugia S. Maria della Misericordia, Perugia, IT, ³National University Cancer Institute Singapore (NCIS), Singapore, SG, ⁴Uniklinik Köln, Cologne, DE, ⁵Peter MacCallum Cancer Center, Melbourne, AU, ⁶National Cancer Centre, Singapore, SG, ⁷AOU Policlinico S. Orsola-Malpighi, Bologna, IT, ⁸Asan Medical Center, Seoul, KR, ⁹Massachusetts General Hospital, Boston, US, ¹⁰Gustave Roussy - Cancer Campus, Villejuif, FR, ¹¹University Hospital 12 De Octubre, Madrid, ES, ¹²Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES, ¹³Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ¹⁴Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ¹⁵Novartis Pharma AG, Basel, CH, ¹⁶Novartis Pharma AG - Novartis Campus, Basel, CH, ¹⁷Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁸Novartis Pharmaceuticals Corp., East Hanover, US, ¹⁹National Taiwan University Hospital, Taipei city, TW

15:53 - 16:05 **1270 - Entrectinib Efficacy in ROS1 Fusion-Positive NSCLC: Analyses in Patients Previously Treated with Crizotinib or with CNS Metastases**

T. Seto¹, R. Dziadziuszko², S. Siena³, M.G. Krebs⁴, A. Drilon⁵, R.C. Doebele⁶, M.R. Patel⁷, B.C. Cho⁸, S.V. Liu⁹, M.-J. Ahn¹⁰, C.-H. Chiu¹¹, A.F. Farago¹², K. Goto¹³, M. Fakih¹⁴, G.A. Otterson¹⁵, L. Bazhenova¹⁶, D.S.W. Tan¹⁷, A. Aziez¹⁸, S. Osborne¹⁸, F. De Braud³, ¹National Kyushu Cancer Center, Fukuoka, JP, ²Medical University of Gdansk, Gdansk, PL, ³Università deli Studi di Milano, Milan, IT, ⁴Division of Cancer Sciences, The University of Manchester, and The Christie NHS Foundation Trust, Manchester, GB, ⁵Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ⁶University of Colorado, Aurora, US, ⁷University of Minnesota, Minnesota, US, ⁸Yonsei Cancer Center Yonsei University, Seoul, KR, ⁹Georgetown University, Washington, US, ¹⁰Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ¹¹Taipei Veterans General Hospital, Taipei, TW, ¹²Massachusetts General Hospital Cancer Center, Boston, US, ¹³National Cancer Center Hospital East, Kashiwa, JP, ¹⁴City of Hope Comprehensive Cancer Center, Duarte, US, ¹⁵Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, US, ¹⁶Moore's Cancer Center - UC San Diego Health, La Jolla, US, ¹⁷NCCS - National Cancer Centre Singapore, Singapore, SG, ¹⁸F. Hoffmann-La Roche, Basel, CH



16:05 - 16:20 **Invited Discussant 1260 and 1270**
T. Newsom-Davis, Chelsea and Westminster Hospital - NHS Trust, London, GB

16:20 - 16:45 Coffee break **Hall 1**
16:45 - 17:45 How radiation therapy competes with surgery in stage III **Room B**
Moderation: R. Rami-Porta¹, J. Van Loon², G. Mountzios³, ¹Hospital Mutua de Terrassa, Terrassa, ES, ²Maastricht University Medical Centre (MUMC)-MAASTRO clinic, Maastricht, NL, ³Medical Oncology, University of Athens School of Medicine Clinical Therapeutics, Athens, GR

16:45 - 17:00 **Case presentation**
G. Mountzios, University of Athens School of Medicine Clinical Therapeutics, Athens, GR

17:00 - 17:15 **Perspective 1 (Radiation oncology)**
J. Van Loon, Maastricht University Medical Centre (MUMC)-MAASTRO clinic, Maastricht, NL

17:15 - 17:30 **Perspective 2 (Surgery)**
R. Rami-Porta, Hospital Mutua de Terrassa, Terrassa, ES

17:30 - 17:45 **Discussion**

16:45 - 17:45 Should I base my decision on genotyping at time of relapse in oncogene-addicted NSCLC? **Room A**
Moderation: A. Greystoke, Medical Oncology Department, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB

16:45 - 16:55 **Introduction and first vote**
A. Greystoke, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB

16:55 - 17:15 **Yes**
M. Wislez, Hopital Tenon, Paris, FR

17:15 - 17:35 **No**
J. Wolf, Uniklinik Köln, Cologne, DE

17:35 - 17:45 **Second vote and conclusions**
A. Greystoke, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB

16:45 - 17:45 Mini oral 2 **Room C**
Moderation: M. O'Brien¹, L. Greillier², ¹Royal Marsden Hospital NHS Foundation Trust,



London, GB, ²Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR

- 16:45 - 16:50 **130 - Blood Levels of Soluble PD-L1, NK and CD8+PD1+ Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients**
G. Mazzaschi¹, R. Minari², P. Bordi¹, V. Ferri², A. Squadrilli², L. Gnetti³, M. Bersanelli³, A. Cavazzoni², S. Buti¹, A. Leonetti², A. Cosenza², L. Ferri², E. Rapacchi², A. Zecca², C. Mori², P.G. Petronini¹, G. Missale², F. Quaini¹, M. Tiseo¹, ¹AOU di Parma, Parma, IT, ²University Hospital of Parma, Parma, IT, ³Azienda Ospedaliera di Parma, Parma, IT
- 16:50 - 16:55 **660 - International real-world study of DLL3 expression in patients with small cell lung cancer**
F. Rojo¹, M. Corassa², D. Mavroudis³, A.B. Oz⁴, B. Biesma⁵, L. Brcic⁶, P. Pauwels⁷, V. Sailer⁸, J.R. Gosney⁹, D. Miljkovic¹⁰, C. Hader¹¹, M. Wu¹², T. Almarez¹², F. Penault-Llorca¹³, ¹Hospital Universitario Fundación Jiménez Díaz, Madrid, ES, ²A. C. Camargo Cancer Center, Sao Paulo, BR, ³University Hospital of Heraklion, Heraklion, GR, ⁴University Of Istanbul Cerrahpasa Medical Faculty, Istanbul, TR, ⁵Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, NL, ⁶Medical University of Graz, Graz, AT, ⁷University Hospital Antwerp (UZA), Edegem, BE, ⁸University Hospital Schleswig-Holstein, Lübeck, DE, ⁹Royal Liverpool University Hospital, Liverpool, GB, ¹⁰AbbVie AG, Baar, CH, ¹¹AbbVie Inc USA, North Chicago, US, ¹²AbbVie Inc, North Chicago, US, ¹³Centre Jean Perrin, Clermont-Ferrand, FR
- 16:55 - 17:00 **670 - Phase Ib expansion study of adavosertib plus olaparib in patients with extensive-stage or relapsed small-cell lung cancer**
B. Li¹, E. Hamilton², J. Wang³, G. Falchook⁴, A. Oza⁵, E. Imedio⁶, S. Kumar⁶, G. Mugundu⁷, E. De Bruin⁶, D. Spigel⁸, S. Fu⁹, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ³Florida Cancer Specialists, Sarasota, US, ⁴Sarah Cannon Research Institute, New York, US, ⁵Princess Margaret Cancer Center, Toronto, CA, ⁶AstraZeneca, Cambridge, GB, ⁷AstraZeneca, Boston, US, ⁸Sarah Cannon Research Institute, Nashville, US, ⁹The University of Texas MD Anderson Cancer Center, Houston, US
- 17:00 - 17:05 **1020 - Outcomes with durvalumab following chemoradiotherapy in Stage IIIA-N2 NSCLC: an exploratory analysis from PACIFIC**
S. Senan¹, M. Ozguroglu², D. Daniel³, A. Villegas⁴, D. Vicente⁵, S. Murakami⁶, R. Hui⁷, C. Faivre-Finn⁸, L. Paz-Ares⁹, Y.-L. Wu¹⁰, H. Mann¹¹, P. Dennis¹², S. Antonia¹³, ¹Cancer Center Amsterdam Locatie VUmc, Amsterdam, NL, ²University Of Istanbul Cerrahpasa Medical Faculty, Istanbul, TR, ³Tennessee Oncology, Chattanooga, US, ⁴Cancer Specialists of North Florida, Jacksonville, US, ⁵Hospital Universitario Virgen Macarena, Sevilla, ES, ⁶Kanagawa Cancer Center Clinical Research Institute, Yokohama, JP, ⁷Westmead Hospital, Westmead, AU, ⁸The Christie NHS Foundation Trust, Manchester, GB, ⁹University Hospital 12 De Octubre, Madrid, ES, ¹⁰Guangdong Lung Cancer Institute, Guangzhou, CN, ¹¹AstraZeneca, Cambridge, GB, ¹²AstraZeneca USA, Gaithersburg, US, ¹³Duke University Medical Center - Trent Center, Durham, US
- 17:05 - 17:10 **2250 - Heterogeneity of evolutionary trajectories and immune profiles of brain**



metastases in lung adenocarcinoma

T. Jiang, C. Zhou, Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN

17:10 - 17:15 **2260 - Time to Central Nervous System (CNS) Progression and Competing Risks Analysis in Patients With ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) Receiving Entrectinib**

F. Barlesi¹, F. De Braud², S. Siena², R. Doebele³, A. Aziez⁴, X. Huang⁵, S. Osborne⁴, A. Drilon⁶, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Università deli Studi di Milano, Milan, IT, ³University of Colorado, Aurora, US, ⁴F. Hoffmann-La Roche, Basel, CH, ⁵Genentech, South San Francisco, US, ⁶Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, US

17:15 - 17:20 **2330 - Pembrolizumab for advanced mesothelioma: results from the phase 2 KEYNOTE-158 study**

T. Yap¹, K. Nakagawa², N. Fujimoto³, K. Kuribayashi⁴, T. Guren⁵, L. Calabrò⁶, R.S. Frommer⁷, B. Gao⁸, S. Kao⁹, I. Matos¹⁰, A. Marabelle¹¹, A. Chatterjee¹², F. Jin¹³, K. Norwood¹², H.L. Kindler¹⁴, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Kindai University School of Medicine, Osaka, JP, ³Okayama Rosai Hospital, Okayama, JP, ⁴Hyogo College of Medicine, Hyogo, JP, ⁵Oslo University Hospital, Oslo, NO, ⁶University Hospital of Siena, Siena, IT, ⁷Chaim Sheba Medical Center, Ramat Gan, IL, ⁸Blacktown Hospital, Blacktown, AU, ⁹Chris O'Brien Lifehouse, Camperdown, AU, ¹⁰Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹¹Institut Gustave Roussy, Villejuif, FR, ¹²Merck & Co., Inc., Kenilworth, US, ¹³Merck & Co., Inc., Kenilworth, Kenilworth, US, ¹⁴University of Chicago, Chicago, US

17:20 - 17:25 **2340 - High-dose pembrolizumab shows impressive survival times in pretreated patients with malignant mesothelioma, PET-CT using PERCIST-derived metabolic tumor volume (MTV) response detects early responders.**

D.C. Christoph¹, F. Barbato¹, M.-K. Chodyla¹, W. Fendler¹, L. Kessler¹, M. Metzenmacher¹, F. Krefting¹, T. Hager¹, K. Herrmann¹, J. Ferdinandus², ¹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ²Universitätsklinikum Bonn, Bonn, DE

17:25 - 17:45 **Discussion led by Moderators**

M. O'Brien, Royal Marsden Hospital NHS Foundation Trust, London, GB

18:00 - 19:00 Medscape Oncology Global - Looking closely at the options for the patient with ALK-positive NSCLC Room A

Moderation: S. Popat, Medicine, Royal Marsden Hospital NHS Foundation Trust, London, GB

18:00 - 18:06 **With more options come more questions: Challenges for the patient with De Novo ALK-positive metastatic NSCLC**

S. Popat, Royal Marsden Hospital NHS Foundation Trust, London, GB

18:06 - 18:10 **Debating the first-line treatment options for the patient with ALK-positive**



metastatic NSCLC

S. Popat, Royal Marsden Hospital NHS Foundation Trust, London, GB

- 18:10 - 18:18 **What do the latest clinical trial data show regarding the efficacy and safety of ALK inhibitors in the first-line?**
R. Camidge¹, M.R. Garcia Campelo², ¹University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US, ²Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES
- 18:18 - 18:25 **Should the site of metastasis influence our choice?**
R. Camidge¹, M.R. Garcia Campelo², ¹University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US, ²Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES
- 18:25 - 18:30 **What about quality of life and other patient factors?**
R. Camidge¹, M.R. Garcia Campelo², ¹University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US, ²Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES
- 18:30 - 18:35 **Anticipating, monitoring, and managing adverse events**
R. Camidge¹, M.R. Garcia Campelo², ¹University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US, ²Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES
- 18:35 - 18:42 **So which ALK inhibitor for which patient?**
R. Camidge¹, M.R. Garcia Campelo², ¹University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US, ²Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES
- 18:42 - 18:49 **What does this mean for second-line treatment?**
R. Camidge¹, M.R. Garcia Campelo², ¹University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US, ²Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES
- 18:49 - 18:59 **Addressing your questions**
S. Popat, Royal Marsden Hospital NHS Foundation Trust, London, GB
- 18:59 - 19:00 **Concluding remarks and close**
S. Popat, Royal Marsden Hospital NHS Foundation Trust, London, GB



- 18:00 - 19:00** **MSD - Defining the standard of care in lung cancer** **Room C**
Moderation: L. Paz-Ares, Medical Oncology Dept., University Hospital 12 De Octubre, Madrid, ES
- 18:00 - 18:05 **Welcome and opening**
L. Paz-Ares, University Hospital 12 De Octubre, Madrid, ES
- 18:05 - 18:35 **Treatment modalities in 1L lung cancer and patient management based on case studies**
A. Calles Blanco¹, M. Gottfried², ¹Hospital General Universitario Gregorio Marañón, Madrid, ES, ²Meir Medical Center, Kfar Saba, IL
- 18:35 - 18:50 **Emerging treatment modalities for lung cancer**
L. Paz-Ares, University Hospital 12 De Octubre, Madrid, ES
- 18:50 - 19:00 **Q&A and closing remarks**
L. Paz-Ares¹, M. Gottfried², A. Calles Blanco³, ¹University Hospital 12 De Octubre, Madrid, ES, ²Meir Medical Center, Kfar Saba, IL, ³Hospital General Universitario Gregorio Marañón, Madrid, ES



17.04.2020

08:00 - 09:30 **Forgotten parts of lung cancer patient's pathway** **Room K**
Moderation: S. Vallone, Oncology Department, LuCE, Bern, CH

08:00 - 08:05 **Introduction**

S. Vallone, LuCE, Bern, CH

08:05 - 08:20 **The role of the radiotherapy in LC treatment**

A. Britten, Royal Sussex County Hospital - Brighton and Sussex University Hospitals NHS Trust, Brighton, GB

08:20 - 08:35 **The importance of the psycho-oncology**

M. Rajalin, Lung Cancer Association, Stockholm, Sverige, SE

08:35 - 08:50 **Importance of physio led care: From pre to post rehab**

G. Sheill, Trinity College Dublin, Dublin, IE

08:50 - 09:05 **What can you do in your work when getting lung cancer**

09:05 - 09:20 **Patient perspective**

09:20 - 09:25 **Sum up and closing**



08:30 - 09:30 Does the cost of care influence clinical decision? Room A
Moderation: E. Smit, Pulmonary Diseases Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

08:30 - 08:40 **Introduction and first vote**
E. Smit, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

08:40 - 09:00 **Yes**
S. Popat, Royal Marsden Hospital NHS Foundation Trust, London, GB

09:00 - 09:20 **No**
V. Gregorc, IRCCS Ospedale San Raffaele, Milan, IT

09:20 - 09:30 **Second vote and conclusions**
E. Smit, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

08:30 - 09:30 Where is the optimal place for I-O: Before or after surgery? Room C
Moderation: M. O'Brien¹, E. Vallieres², J. Remon Masip³, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Swedish Cancer Institute, Seattle, US, ³Dept. Oncology, CIOCC- Centro Integral Oncológico Clara Campal, Barcelona, ES

08:30 - 08:45 **Case presentation**
J. Remon Masip, CIOCC- Centro Integral Oncológico Clara Campal, Barcelona, ES

08:45 - 09:00 **Perspective 1 (Medical oncology, adjuvant treatment)**
M. O'Brien, Royal Marsden Hospital NHS Foundation Trust, London, GB

09:00 - 09:15 **Perspective 2 (Surgery)**
E. Vallieres, Swedish Cancer Institute, Seattle, US

09:15 - 09:30 **Discussion**

09:45 - 10:15 Where are we with artificial intelligence (AI) in 2019? Potential applications in healthcare Room B
Moderation: C. Faivre-Finn, Clinical Oncology Department, The Christie NHS Foundation Trust, Manchester, GB

09:45 - 10:15 **Where are we with artificial intelligence (AI) in 2019? Potential applications in healthcare**

10:15 - 10:45 Coffee break Hall 1



10:45 - 12:15 Tumoral heterogeneity response and resistance to treatment: Consequences for practice Room B

Moderation: R. Büttner¹, M. Garassino², ¹Institut Für Pathologie, University Hospital Cologne, Köln, DE, ²Thoracic Unit, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

10:45 - 11:05 **Intratumoral heterogeneity in lung cancer**
M. Peifer, University Hospital Cologne, Cologne, DE

11:05 - 11:25 **Role of innate immunity in predicting response to immunotherapy**
M. Garassino, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

11:25 - 11:45 **Oligoclonal evolution of resistance to targeted therapies**

11:45 - 12:05 **Heterogeneity in responses to immunotherapy**
S. Quezada, University College London, London, GB

12:05 - 12:15 **Q&A**

10:45 - 12:15 Why are there so many approaches to oligometastatic disease? Room A

Moderation: A.-M. Dingemans¹, E. Fadel², ¹Pulmonology Department, Erasmus MC - University Medical Center, Rotterdam, NL, ²Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, FR

10:45 - 11:05 **How can we define oligometastasis and how is it different from oligoprogression?**
A.-M. Dingemans, Erasmus MC - University Medical Center, Rotterdam, NL

11:05 - 11:25 **Is there a role for surgery?**
P. Van Schil, University Hospital Antwerp (UZA), Edegem, BE

11:25 - 11:45 **When should I initiate, stop and resume systemic treatment?**
B. Besse, Institut Gustave Roussy, Villejuif, FR

11:45 - 12:05 **Current status of radiation therapy for oligometastasis**
F. Mcdonald, Royal Marsden Hospital NHS Foundation Trust, London, GB

12:05 - 12:15 **Q&A**



10:45 - 12:15 Do we really understand patient reported outcomes (PROs)? Room C
Moderation: A. Greystoke, Medical Oncology Department, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB

10:45 - 11:05 **Optimal tools and innovative approaches**
G. Mody, UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US

11:05 - 11:25 **Challenges in assessing PROs**
J. Yorke, The Christie NHS Foundation Trust, Manchester, GB

11:25 - 11:45 **How could we use PROs in daily practice?**
A. Girgis, Ingham Institute for Applied Medical Research - Western Sydney University, Liverpool, AU

11:45 - 12:05 **Patient support groups and social media**
D. Montague, UK ALK POSITIVE, Surrey, GB

12:05 - 12:15 **Q&A**

10:45 - 12:15 Supportive care in the era of novel therapies for thoracic cancers Room K
Moderation: A. Charalambous, Nursing Science, Cyprus University of Technology - Nursing Science, Limassol, CY

10:45 - 11:05 **New symptoms - New challenges**

11:05 - 11:25 **Utilising technology to meet the unmet needs of patients with thoracic cancers**
A. Charalambous, Cyprus University of Technology - Nursing Science, Limassol, CY

11:25 - 11:45 **Nutritional support interventions in advanced lung cancer**
C. Cloconi, Cyprus University of Technology, Limassol, CY

11:45 - 12:05 **Supporting the role of the caregiver across the cancer continuum**
L.D. Csaba, Babes-Bolyai University, Cluj-Napoca, RO

12:05 - 12:15 **Q&A**

12:15 - 13:00 Lunch break Hall 1



12:15 - 13:00 **YO Vesalius Talk: How to run translational research studies in lung cancer? Where to start?** **Hall 1 - Catch up corner**

Moderation: K.H.J. Lim, Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, GB

12:15 - 13:00 **Panelists**

F. Blackhall¹, J. Wolf², ¹The Christie NHS Foundation Trust, Manchester, GB, ²Uniklinik Köln, Cologne, DE

13:00 - 14:00 **AstraZeneca - Targeting lung cancer: Different approaches for different patients** **Room A**

Moderation: S. Peters, Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

13:00 - 13:02 **Welcome and introduction**

S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

13:02 - 13:14 **Extensive-stage SCLC: Changing the paradigm with IO combinations**

S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

13:14 - 13:26 **Unresectable stage III NSCLC: Clinical implementation of new approaches**

J. Vansteenkiste, University Hospitals Leuven, Leuven, BE

13:26 - 13:46 **EGFRm NSCLC: Targeted treatment options to improve outcomes in first-line locally advanced**

D. Planchard, Institut Gustave Roussy, Villejuif, FR

13:46 - 14:00 **Audience Q&A**

S. Peters¹, J. Vansteenkiste², D. Planchard³, ¹Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ²University Hospitals Leuven, Leuven, BE, ³Institut Gustave Roussy, Villejuif, FR



13:00 - 14:00	F. Hoffmann La-Roche - #PutCancerToTheTest: The art of treatment selection in lung cancer	Room C
	Moderation: L. Paz-Ares, Medical Oncology Dept., University Hospital 12 De Octubre, Madrid, ES	
13:00 - 13:05	Introduction <u>L. Paz-Ares</u> , University Hospital 12 De Octubre, Madrid, ES	
13:05 - 13:15	PD-L1 high NSCLC: Options with checkpoint inhibitor monotherapy <u>T. Newsom-Davis</u> , Chelsea and Westminster Hospital - NHS Trust, London, GB	
13:15 - 13:25	Achieving transformational change in ALK+ NSCLC treatment <u>A.-M. Dingemans</u> , Erasmus MC - University Medical Center, Rotterdam, NL	
13:25 - 13:35	New treatments making the difference in ROS1+ NSCLC <u>L. Paz-Ares</u> , University Hospital 12 De Octubre, Madrid, ES	
13:35 - 13:45	Find that patient: Treating NTRK fusion-positive tumours <u>R. Doebele</u> , University of Colorado, Aurora, US	
13:45 - 14:00	Q&A <u>L. Paz-Ares</u> ¹ , <u>T. Newsom-Davis</u> ² , <u>A.-M. Dingemans</u> ³ , <u>R. Doebele</u> ⁴ , ¹ University Hospital 12 De Octubre, Madrid, ES, ² Chelsea and Westminster Hospital - NHS Trust, London, GB, ³ Erasmus MC - University Medical Center, Rotterdam, NL, ⁴ University of Colorado, Aurora, US	



13:00 - 14:30 Early diagnosis and lung cancer screening **Room K**
Moderation: E. Szmytke, Board, LuCE, Bern, CH

13:00 - 13:05 **Introduction**
E. Szmytke, LuCE, Bern, CH

13:05 - 13:25 **The 4th LuCE report**
A.-M. Baird, St. James's Hospital, Dublin, IE

13:25 - 13:45 **Personal experience of early detection**
G. Kranz, Bundesverband Selbsthilfe Lungenkrebs, Berlin, DE

13:45 - 14:05 **Implementation of LC screening in US**
A. Borondy Kitts, Lahey Hospital & Medical Center, Burlington, US

14:05 - 14:25 **How to implement a LC screening program out of US: Advocate perspective**
S. Shilo, Israel Lung Cancer Foundation, Rehovot, IL

14:25 - 14:30 **Sum up and closing**

14:10 - 14:40 Genotyping: From academia to marketing **Room B**
Moderation: F. Barlesi, Gustave Roussy - Cancer Campus, Villejuif, FR

14:10 - 14:40 **Genotyping: From academia to marketing**
T. Mitsudomi, Kindai University - Faculty of Medicine, Osaka, JP



14:45 - 16:15 Hitting the target in 2020 Room B
Moderation: H. Wakelee, Medicine/oncology, Stanford University, Stanford, US

14:45 - 15:05 **EGFR**

15:05 - 15:25 **Gene fusion targets**

S. Novello, Università Degli Studi Di Torino - Orbassano, Orbassano, IT

15:25 - 15:45 **HER2, MET, BRAF**

J. Remon Masip, CIOCC- Centro Integral Oncológico Clara Campal, Barcelona, ES

15:45 - 16:05 **RAS**

N. Leighl, University Health Network - Princess Margaret Cancer Center, Toronto, CA

16:05 - 16:15 **Q&A**

14:45 - 16:15 What is the place of the pathologist in 2020? Room A
Moderation: R. Büttner¹, L. Bubendorf², ¹Institut Für Pathologie, University Hospital Cologne, Köln, DE, ²Pathology Dept., University Hospital Basel - Institute of Pathology, Basel, CH

14:45 - 15:05 **Will artificial intelligence (AI) make pathologists redundant?**

R. Büttner, Uniklinik Köln, Köln, DE

15:05 - 15:25 **Will liquid biopsies make histopathology redundant?**

P. Hofman, CHR Hôpital Pasteur, Nice, FR

15:25 - 15:45 **State of the art: Use of automated tumour recognition and digital pathology**

M. Salto-Tellez, Queen's University Belfast, Belfast, GB

15:45 - 16:05 **Can pathologists provide the full spectrum of molecular pathology diagnostics?**

L. Bubendorf, University Hospital Basel - Institute of Pathology, Basel, CH

16:05 - 16:15 **Q&A**



14:45 - 16:15 Resistance to immune checkpoint inhibitor treatment Room C

Moderation: Y. Yatabe¹, L. Paz-Ares², ¹Dept Of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, JP, ²Medical Oncology Dept., University Hospital 12 De Octubre, Madrid, ES

14:45 - 15:05 **Intrinsic resistance in relation to driver mutations**

Y. Yatabe, National Cancer Center Hospital, Tokyo, JP

15:05 - 15:25 **Intrinsic resistance in relation to TMB**

M. Ilie, CHU Nice - Hôpital Pasteur, Nice, FR

15:25 - 15:45 **Mechanisms of acquired resistance against IOI treatment: An overview**

K. Politi, Yale University School of Medicine - Yale Cancer Center, New Haven, US

15:45 - 16:05 **Treatment perspectives for the patients failed with IOI treatment**

L. Paz-Ares, University Hospital 12 De Octubre, Madrid, ES

16:05 - 16:15 **Q&A**



14:45 - 16:15 Supportive and nursing care for patients with lung cancer: Perspectives from the French speaking community Room K

Moderation: M. Eicher¹, P. Dielenseger², ¹Oncology, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ²Early Drug Development Department (ditep), Institut Gustave Roussy, Villejuif, FR

14:45 - 15:05 Measuring patient reported outcomes for patients with thoracic cancers: Hope or hype?

M. Eicher, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

15:05 - 15:25 How to engage patients in care

15:25 - 15:45 Supportive Care Guidelines: What's in for the nurses

F. Scotté, Hopital Foch, Suresnes, FR

15:45 - 16:05 PRO-CTCAEs for the monitoring of patients treated with immune checkpoint inhibitors: Results of a European Delphi Study

A. Lopes, Institute of Higher Education and Research in Healthcare - IUFRS, CHUV, Lausanne, CH

16:05 - 16:15 Q&A

16:15 - 16:45 Coffee break Hall 1



16:45 - 18:15 Multiple ways to manage oligometastatic disease Room B

Moderation: T. Berghmans¹, A. Levy², ¹Department Of Thoracic Oncology, Institute Jules Bordet, Brussels, BE, ²Radiation Oncology, Gustave Roussy - Cancer Campus, Villejuif, FR

16:45 - 16:55 **Presentation of case**

A. Levy, Gustave Roussy - Cancer Campus, Villejuif, FR

16:55 - 17:10 **Should radiotherapy be the standard of care?**

C. Le Pechoux, Institut Gustave Roussy, Villejuif, FR

17:10 - 17:25 **Is there a role for surgery?**

J. Edwards, Northern General Hospital-Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB

17:25 - 17:40 **Where systemic therapy fits**

T. Berghmans, Institute Jules Bordet, Brussels, BE

17:40 - 17:55 **Management decision**

17:55 - 18:15 **Discussion**



16:45 - 18:15 Should we use liquid biopsy? Room A

Moderation: F. Barlesi¹, H. Wakelee², ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Medicine/oncology, Stanford University, Stanford, US

16:45 - 17:05 **Technical and pre-analytic issues in daily practice**

F. Lopez-Rios, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

17:05 - 17:25 **Molecular genotyping at diagnosis on liquid biopsies**

N. Peled, Soroka University Medical Center, Beer Sheva, IL

17:25 - 17:45 **TMB and predictive factors for ICI on liquid biopsies**

F. Blackhall, The Christie NHS Foundation Trust, Manchester, GB

17:45 - 18:05 **Liquid biopsies at resistance on TKIs**

F. Grossi, Ospedale Maggiore Policlinico-Fondazione IRCCS Ca' Granda, Milan, IT

18:05 - 18:15 **Q&A**

16:45 - 18:15 Reshaping clinical trials for the future Room C

Moderation: R. Dziadziuszko¹, T. Mitsudomi², ¹Oncology And Radiotherapy, Medical University of Gdansk, Gdansk, PL, ²Thoracic Surgery Department, Kindai University - Faculty of Medicine, Osaka, JP

16:45 - 17:05 **From early phase to registration in one trial: Myth or reality?**

R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL

17:05 - 17:25 **Exploring new drug indications: Basket and umbrella trials**

J. Mazieres, CHU Toulouse - Hôpital Larrey, Toulouse, FR

17:25 - 17:45 **Immunotherapy trials: Controversies and pitfalls**

M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

17:45 - 18:05 **Trials involving surgery: Current landscape**

S. Hillinger, University Hospital Zurich and University Zurich, Zurich, CH

18:05 - 18:15 **Q&A**



16:45 - 18:15 Supportive challenges in lung cancer care: Case presentations and discussions **Room K**

16:45 - 17:05 **Maintaining functional independence**

17:05 - 17:25 **Impact of surveillance on patients**

17:25 - 17:45 **Optimising prehabilitation**

M. Quist, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DK

17:45 - 18:05 **Life after lung cancer treatment: Preparing patients to survive lung cancer**

18:05 - 18:15 **Q&A**



18.04.2020

08:30 - 09:30 Can we tailor the duration of I-O treatment? Room A

Moderation: B. Besse, Dept Of Cancer Medicine, Institut Gustave Roussy, Villejuif, FR

08:30 - 08:40 **Introduction and first vote**

B. Besse, Institut Gustave Roussy, Villejuif, FR

08:40 - 09:00 **Yes**

E. Smit, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

09:00 - 09:20 **No**

P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES

09:20 - 09:30 **Second vote and conclusions**

B. Besse, Institut Gustave Roussy, Villejuif, FR

08:30 - 09:30 Management of patients with driver mutations Room C

Moderation: J. Khalifa¹, R.A. Stahel², H. Hayashi³, ¹Institut Universitaire du Cancer - Toulouse- Oncopole, Toulouse, FR, ²University Hospital Zürich, Zurich, CH, ³Kindai University School of Medicine - Main Campus, Osaka, JP

08:30 - 08:45 **Case presentation**

H. Hayashi, Kindai University School of Medicine - Main Campus, Osaka, JP

08:45 - 09:00 **Perspective 1 (Radiation oncology)**

J. Khalifa, Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR

09:00 - 09:15 **Perspective 2 (Medical oncology)**

R.A. Stahel, University Hospital Zürich, Zurich, CH

09:15 - 09:30 **Discussion**



09:40 - 11:10 I-O combinations Room A
Moderation: F. Cappuzzo, Oncology And Hematology, Ospedale Santa Maria delle Croci, Ravenna, IT

09:40 - 10:00 **Biological rationale for I-O combinations in solid tumours**
C. Lindsay, The Christie NHS Foundation Trust, Manchester, GB

10:00 - 10:20 **Combination with chemotherapy: Current evidences and beyond**
F. Cappuzzo, Ospedale Santa Maria delle Croci, Ravenna, IT

10:20 - 10:40 **Combination with radiotherapy: Expectations, facts and promises**
G. Hanna, Peter MacCallum Cancer Centre, Melbourne, AU

10:40 - 11:00 **I-O/I-O combinations: Standards and new approaches including TILs**
S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

11:00 - 11:10 **Q&A**

09:40 - 11:10 Is artificial intelligence (AI) here to stay? Room C
Moderation: J. Mazieres, Thoracic Oncology Department, CHU Toulouse - Hôpital Larrey, Toulouse, FR

09:40 - 10:00 **AI: What's in a name?**
S. Benzekry, INRIA Head Office, Le Chesnay, FR

10:00 - 10:20 **Genomics: Predict tumor development**
G. Caravagna, ICR - Institute of Cancer Research, London, GB

10:20 - 10:40 **Radiomics: Image to replace the biopsy?**
R. Sun, Institut Gustave Roussy, Villejuif, FR

10:40 - 11:00 **Critics and concerns about AI**
S. Miyano, University of Tokyo-Research hospital, The Institute of Medical Science, Tokyo, JP

11:00 - 11:10 **Q&A**

11:10 - 11:30 Coffee break Hall 1



11:30 - 12:00 Lung cancer in 2030: More patients to be cured Room A
Moderation: J. Haanen, Medical Oncology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

11:30 - 12:00 **Lung cancer in 2030: More patients to be cured**
P. Jänne, Dana Farber Cancer Institute, Boston, US

12:00 - 12:15 Closing remarks Room A